记事本2020 personal page - To The Moon

记事本2020

记事本2020

No personal profile

971Follow

44Followers

0Topic

0Badge

2021-08-30

666

UBS: Gives WuXi Biologics (02269) a "Buy" rating with a target price of HK$142

2021-08-30

666

Driven by dual business engines and a sound strategic layout, Beijing Energy Clean Energy (0579.HK) saw steady improvement in its interim results.

2021-08-30

666

Why did Haidilao target Zhang Yong's wife and founder?

2021-08-26

666

Morgan Stanley: Gives WuXi Biologics "Overweight" rating, raises target price 3.6% to HK$170

2021-08-25

666

Zhongtai Securities: Maintain the "Buy" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments

2021-08-23

666

[Stocks in Focus] WuXi Biologics (02269.HK) rose 3.13%

2021-03-06

666

Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.

2021-03-06

666

Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3550828792714737","uuid":"3550828792714737","gmtCreate":1587765570145,"gmtModify":1604808867541,"name":"记事本2020","pinyin":"jsb2020jishiben2020","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":44,"headSize":971,"tweetSize":115,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.75%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":811218252,"gmtCreate":1630326149476,"gmtModify":1676530269198,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811218252","repostId":"2163012390","repostType":2,"repost":{"id":"2163012390","kind":"news","pubTimestamp":1630308776,"share":"https://ttm.financial/m/news/2163012390?lang=en_US&edition=fundamental","pubTime":"2021-08-30 15:32","market":"hk","language":"zh","title":"UBS: Gives WuXi Biologics (02269) a \"Buy\" rating with a target price of HK$142","url":"https://stock-news.laohu8.com/highlight/detail?id=2163012390","media":"智通财经","summary":"智通财经APP获悉，瑞银发布研究报告称，予药明生物“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。","content":"<p><html><body>According to Zhitong Finance APP,<a href=\"https://laohu8.com/S/UBS\">UBS</a>A research report was released stating that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) has a \"Buy\" rating with a target price of HK$142, raising its 2021-23 earnings per share forecast by 26% to 38% to reflect stronger-than-expected pandemic and CMO-related projects, and raising its 2020-24 revenue forecast by 11% to reflect stronger-than-expected growth in COVID-19 projects and growth in pharmaceutical manufacturing outsourcing (CMO).</p><p>The report stated that, according to management, there will be at least four to five non-COVID-19-related CMOs by the end of 2022, which is expected to drive the company's long-term profit growth. Management will maintain its 2021 guidance, expecting revenue and net profit to increase by 65% year-on-year. The bank believes that if growth is not affected by supply shortages, the company is expected to outperform the guidance.</p><p>The bank stated that, according to management, there is currently no evidence that the U.S. government will restrict U.S. companies from using CDMO companies based in China. Meanwhile, 20% of WuXi AppTec's customers have considered using the company's production capacity in Europe and the United States to mitigate risks. Considering the nature of the company's CDMO services, if drugs are produced in Europe and the United States and shipped there, they will not be considered exported from China to the United States, which is believed to reduce the risk of drug supply instability.</p><p></body></html></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS: Gives WuXi Biologics (02269) a \"Buy\" rating with a target price of HK$142</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS: Gives WuXi Biologics (02269) a \"Buy\" rating with a target price of HK$142\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-30 15:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>According to Zhitong Finance APP,<a href=\"https://laohu8.com/S/UBS\">UBS</a>A research report was released stating that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) has a \"Buy\" rating with a target price of HK$142, raising its 2021-23 earnings per share forecast by 26% to 38% to reflect stronger-than-expected pandemic and CMO-related projects, and raising its 2020-24 revenue forecast by 11% to reflect stronger-than-expected growth in COVID-19 projects and growth in pharmaceutical manufacturing outsourcing (CMO).</p><p>The report stated that, according to management, there will be at least four to five non-COVID-19-related CMOs by the end of 2022, which is expected to drive the company's long-term profit growth. Management will maintain its 2021 guidance, expecting revenue and net profit to increase by 65% year-on-year. The bank believes that if growth is not affected by supply shortages, the company is expected to outperform the guidance.</p><p>The bank stated that, according to management, there is currently no evidence that the U.S. government will restrict U.S. companies from using CDMO companies based in China. Meanwhile, 20% of WuXi AppTec's customers have considered using the company's production capacity in Europe and the United States to mitigate risks. Considering the nature of the company's CDMO services, if drugs are produced in Europe and the United States and shipped there, they will not be considered exported from China to the United States, which is believed to reduce the risk of drug supply instability.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/549312.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"02269":"药明生物"},"source_url":"http://www.zhitongcaijing.com/content/detail/549312.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163012390","content_text":"智通财经APP获悉，瑞银发布研究报告称，予药明生物(02269)“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包(CMO)增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。该行表示，据管理层指，现时未有证据美国政府将限制美国企业使用以中国为基地的CDMO企业，同时有20%药明的客户已考虑使用公司于欧美的产能以减低风险，考虑公司CDMO服务性质，假如药物于欧美生产并运往当地，将不被视作由中国出口至美国，相信可减低药物供应不稳的风险。","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":3110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811103906,"gmtCreate":1630293590105,"gmtModify":1676530259718,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811103906","repostId":"2163702540","repostType":2,"repost":{"id":"2163702540","kind":"news","pubTimestamp":1630285168,"share":"https://ttm.financial/m/news/2163702540?lang=en_US&edition=fundamental","pubTime":"2021-08-30 08:59","market":"us","language":"zh","title":"Driven by dual business engines and a sound strategic layout, Beijing Energy Clean Energy (0579.HK) saw steady improvement in its interim results.","url":"https://stock-news.laohu8.com/highlight/detail?id=2163702540","media":"格隆汇","summary":"总结来说，整个2021年上半年，京能清洁能源凭借其自身的软硬实力，充分发挥多元化的竞争优势，使得各个业务板块实现稳健增长。","content":"<p><html><body><span>On August 26, Hong Kong stocks<a href=\"https://laohu8.com/S/00579\">Jingneng Clean Energy</a>(0579.HK) announced its 2021 interim results: it achieved operating revenue of RMB 9.34 billion, a year-on-year increase of 12.81%; Profit before tax was RMB1,884 million, representing a year-on-year increase of 13.90%; Profit attributable to ordinary shareholders of the company was RMB 1.488 billion, representing a year-on-year increase of 14.90%; Basic and diluted earnings per share were RMB18.05 cents.</span></p><p>This is an excellent report card. In the fiercely competitive market environment, Beijing Energy Clean Energy achieved double-digit year-on-year growth in both revenue and net profit in the first half of this year. It can be said that it has made progress while maintaining stability and has strong momentum to move forward.</p><p><b><font color=\"#ff0000\">1. Steady business growth and further consolidation of industry position</font></b></p><p>The semi-annual performance report released by Beijing Energy Clean Energy shows that while its operating performance has grown steadily, it has also performed well in multiple business dimensions and has been continuously optimized.</p><p><b>Installed capacity has steadily increased.</b>As of June 30, 2021, the company's total installed capacity was 11.215 million kilowatts, a year-on-year increase of 14%. Among them, the wind power business segment added 349,000 kilowatts of installed capacity, all of which came from self-built projects.</p><p><b>Electricity generation showed a significant increase.</b>As of June 30, 2021, the company's total controlled power generation reached 16.179 billion kilowatt-hours, representing a year-on-year increase of 17.73%.</p><p>Among them, the power generation of the gas power generation and heating business segment increased by 8.08% year-on-year;<b>The wind power generation business segment's power generation increased by 44.43% year-on-year; The photovoltaic power generation business segment's power generation increased by 37.87% year-on-year, significantly higher than the national industry level during the same period.</b></p><p><b>In summary,</b>Throughout the first half of 2021, Beijing Energy Clean Energy leveraged its own soft and hard strengths to fully utilize its diversified competitive advantages, enabling its various business segments to achieve steady growth.</p><p>In particular, the photovoltaic sector exceeded the national average during the same period, fully catering to the development concepts of \"30, 60\" and \"carbon peaking and carbon neutrality\", and further consolidating the company's leading position in the industry as a local new energy state-owned enterprise.</p><p><b><font color=\"#ff0000\">2. Driven by both independent development and project mergers and acquisitions, business synergy is highlighted.</font></b></p><p>When judging a company's growth, there are often two points worth paying attention to. First, the growth of endogenous driving forces, that is, relying on the company's own accumulation and accumulating strength before making a breakthrough. Secondly, external mergers and acquisitions integrate markets, resources, and technology through mergers and acquisitions, achieving rapid development under efficient corporate internal control capabilities.</p><p><b>In terms of endogenous growth, we will continue to accelerate the pace of independent project development and construction.</b>According to the interim report, as of the first half of 2021, the company had independently developed 18 wind power and photovoltaic projects that had obtained construction quotas, with an installed capacity of 1.754 million kilowatts.</p><p>Among them, the \"Beijing-Zhangjiakou Olympic Wind Power Project\" undertaken by the company utilizes the abundant wind power resources of the Zhangjiakou area and takes advantage of the joint bid by Beijing and Hebei Province to host the 2022 Olympic and Paralympic Winter Games. It transmits wind power from the Zhangjiakou area to the Beijing power grid for winter heating. At the same time, it contributes the strength of a state-owned enterprise in the capital to the 2022 Beijing Olympic and Paralympic Winter Games Committee, which achieved green electricity coverage for all venues for the first time in Olympic history.</p><p>Moreover, the construction of this project has enabled the development and utilization of the local abundant wind energy resources, playing a significant role in promoting the development of the regional economy. At the same time, it has greatly optimized Beijing's energy structure, which is more conducive to the implementation and effectiveness of the central government's strategic plan for the coordinated development of the \"Beijing-Tianjin-Hebei integration\".</p><p>It is understood that the total installed capacity of the project is 1.2 million kilowatts. Among them, Beijing Energy Clean Energy has a self-built capacity of 775,000 kilowatts. To date, it has completed the transfer of the Dongxu Shangyi 200,000 kilowatt wind power project and the Guoxin Haojiaying 100,000 kilowatt wind power project. Beijing Energy Clean Energy manages an installed capacity of 1.075 million kilowatts, with a total investment of approximately 9 billion yuan.</p><p><b>In terms of external expansion, we will vigorously expand our business through project mergers and acquisitions. As of the first half of 2021,</b>A total of 13 wind power and photovoltaic projects are currently undergoing mergers and acquisitions, with an installed capacity of 1.486 million kilowatts. In July of this year, the company entered into an equity transfer agreement with Ningxia Jiaze for Kaiyang and Boyang, acquiring the 297.5MW wind power and photovoltaic project in Hongsipu, Ningxia, and the 99MW wind power project in Tongxin, Ningxia, contributing to the growth of Beijing Energy Clean Energy's installed capacity in the second half of the year.</p><p>It is worth mentioning that,<b>This acquisition will facilitate the intensive management of Beijing Energy Clean Energy's Northwest Branch and will create good synergies with the company's existing assets. It can not only achieve the goals of complementary advantages, learning from each other's strengths and weaknesses, reducing costs and increasing efficiency, and enabling business synergy, but also enable the company to form a nationwide and comprehensive strategic layout.</b></p><p><b>In fact, mergers and acquisitions are an inevitable path to increased concentration in the new energy industry and a manifestation of internal reshuffling within the industry.</b>With the increasing cost of self-built projects across the industry, seeking to acquire projects through mergers and acquisitions, or even acquiring other industries to fill gaps in business layout and expand scale, has become one of the new business models for new energy companies.</p><p>For new energy companies, shifting from pure competition to cooperation not only allows them to leverage each other's strengths, but also mitigates investment risks to a certain extent and maximizes profits. At the same time, we can leverage the strengths of each company to make the company the best it can be.</p><p>Therefore, in the long run, with changes in the market environment, the future development model of new energy companies will be not only to hone their internal capabilities and enhance their core strength, but also to acquire more resources through mergers and acquisitions, restructuring and other means, and to try in multiple fields. \"Dual-wheel drive\" or even \"four-wheel drive\" will be the future growth path of new energy companies. Beijing Energy Clean Energy has officially embarked on this high-speed road of \"becoming stronger and bigger\".</p><p></body></html></p>","source":"stock_gelonghui","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Driven by dual business engines and a sound strategic layout, Beijing Energy Clean Energy (0579.HK) saw steady improvement in its interim results.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDriven by dual business engines and a sound strategic layout, Beijing Energy Clean Energy (0579.HK) saw steady improvement in its interim results.\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">格隆汇</strong><span class=\"h-time small\">2021-08-30 08:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><span>On August 26, Hong Kong stocks<a href=\"https://laohu8.com/S/00579\">Jingneng Clean Energy</a>(0579.HK) announced its 2021 interim results: it achieved operating revenue of RMB 9.34 billion, a year-on-year increase of 12.81%; Profit before tax was RMB1,884 million, representing a year-on-year increase of 13.90%; Profit attributable to ordinary shareholders of the company was RMB 1.488 billion, representing a year-on-year increase of 14.90%; Basic and diluted earnings per share were RMB18.05 cents.</span></p><p>This is an excellent report card. In the fiercely competitive market environment, Beijing Energy Clean Energy achieved double-digit year-on-year growth in both revenue and net profit in the first half of this year. It can be said that it has made progress while maintaining stability and has strong momentum to move forward.</p><p><b><font color=\"#ff0000\">1. Steady business growth and further consolidation of industry position</font></b></p><p>The semi-annual performance report released by Beijing Energy Clean Energy shows that while its operating performance has grown steadily, it has also performed well in multiple business dimensions and has been continuously optimized.</p><p><b>Installed capacity has steadily increased.</b>As of June 30, 2021, the company's total installed capacity was 11.215 million kilowatts, a year-on-year increase of 14%. Among them, the wind power business segment added 349,000 kilowatts of installed capacity, all of which came from self-built projects.</p><p><b>Electricity generation showed a significant increase.</b>As of June 30, 2021, the company's total controlled power generation reached 16.179 billion kilowatt-hours, representing a year-on-year increase of 17.73%.</p><p>Among them, the power generation of the gas power generation and heating business segment increased by 8.08% year-on-year;<b>The wind power generation business segment's power generation increased by 44.43% year-on-year; The photovoltaic power generation business segment's power generation increased by 37.87% year-on-year, significantly higher than the national industry level during the same period.</b></p><p><b>In summary,</b>Throughout the first half of 2021, Beijing Energy Clean Energy leveraged its own soft and hard strengths to fully utilize its diversified competitive advantages, enabling its various business segments to achieve steady growth.</p><p>In particular, the photovoltaic sector exceeded the national average during the same period, fully catering to the development concepts of \"30, 60\" and \"carbon peaking and carbon neutrality\", and further consolidating the company's leading position in the industry as a local new energy state-owned enterprise.</p><p><b><font color=\"#ff0000\">2. Driven by both independent development and project mergers and acquisitions, business synergy is highlighted.</font></b></p><p>When judging a company's growth, there are often two points worth paying attention to. First, the growth of endogenous driving forces, that is, relying on the company's own accumulation and accumulating strength before making a breakthrough. Secondly, external mergers and acquisitions integrate markets, resources, and technology through mergers and acquisitions, achieving rapid development under efficient corporate internal control capabilities.</p><p><b>In terms of endogenous growth, we will continue to accelerate the pace of independent project development and construction.</b>According to the interim report, as of the first half of 2021, the company had independently developed 18 wind power and photovoltaic projects that had obtained construction quotas, with an installed capacity of 1.754 million kilowatts.</p><p>Among them, the \"Beijing-Zhangjiakou Olympic Wind Power Project\" undertaken by the company utilizes the abundant wind power resources of the Zhangjiakou area and takes advantage of the joint bid by Beijing and Hebei Province to host the 2022 Olympic and Paralympic Winter Games. It transmits wind power from the Zhangjiakou area to the Beijing power grid for winter heating. At the same time, it contributes the strength of a state-owned enterprise in the capital to the 2022 Beijing Olympic and Paralympic Winter Games Committee, which achieved green electricity coverage for all venues for the first time in Olympic history.</p><p>Moreover, the construction of this project has enabled the development and utilization of the local abundant wind energy resources, playing a significant role in promoting the development of the regional economy. At the same time, it has greatly optimized Beijing's energy structure, which is more conducive to the implementation and effectiveness of the central government's strategic plan for the coordinated development of the \"Beijing-Tianjin-Hebei integration\".</p><p>It is understood that the total installed capacity of the project is 1.2 million kilowatts. Among them, Beijing Energy Clean Energy has a self-built capacity of 775,000 kilowatts. To date, it has completed the transfer of the Dongxu Shangyi 200,000 kilowatt wind power project and the Guoxin Haojiaying 100,000 kilowatt wind power project. Beijing Energy Clean Energy manages an installed capacity of 1.075 million kilowatts, with a total investment of approximately 9 billion yuan.</p><p><b>In terms of external expansion, we will vigorously expand our business through project mergers and acquisitions. As of the first half of 2021,</b>A total of 13 wind power and photovoltaic projects are currently undergoing mergers and acquisitions, with an installed capacity of 1.486 million kilowatts. In July of this year, the company entered into an equity transfer agreement with Ningxia Jiaze for Kaiyang and Boyang, acquiring the 297.5MW wind power and photovoltaic project in Hongsipu, Ningxia, and the 99MW wind power project in Tongxin, Ningxia, contributing to the growth of Beijing Energy Clean Energy's installed capacity in the second half of the year.</p><p>It is worth mentioning that,<b>This acquisition will facilitate the intensive management of Beijing Energy Clean Energy's Northwest Branch and will create good synergies with the company's existing assets. It can not only achieve the goals of complementary advantages, learning from each other's strengths and weaknesses, reducing costs and increasing efficiency, and enabling business synergy, but also enable the company to form a nationwide and comprehensive strategic layout.</b></p><p><b>In fact, mergers and acquisitions are an inevitable path to increased concentration in the new energy industry and a manifestation of internal reshuffling within the industry.</b>With the increasing cost of self-built projects across the industry, seeking to acquire projects through mergers and acquisitions, or even acquiring other industries to fill gaps in business layout and expand scale, has become one of the new business models for new energy companies.</p><p>For new energy companies, shifting from pure competition to cooperation not only allows them to leverage each other's strengths, but also mitigates investment risks to a certain extent and maximizes profits. At the same time, we can leverage the strengths of each company to make the company the best it can be.</p><p>Therefore, in the long run, with changes in the market environment, the future development model of new energy companies will be not only to hone their internal capabilities and enhance their core strength, but also to acquire more resources through mergers and acquisitions, restructuring and other means, and to try in multiple fields. \"Dual-wheel drive\" or even \"four-wheel drive\" will be the future growth path of new energy companies. Beijing Energy Clean Energy has officially embarked on this high-speed road of \"becoming stronger and bigger\".</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://www.gelonghui.com/news/detail.html?id=608034\">格隆汇</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f01e4b782ba393cb7794f7764a5d7d90","relate_stocks":{"00579":"京能清洁能源"},"source_url":"https://www.gelonghui.com/news/detail.html?id=608034","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163702540","content_text":"8月26日，港股京能清洁能源(0579.HK)公布2021中期业绩报告：实现营业收入人民币93.40亿元，同比增长12.81%；除税前溢利为人民币18.84亿元，同比增长13.90%；公司普通股股东应占溢利为人民币14.88亿元，同比增长14.90%；每股基本及摊薄盈利人民币18.05分。这是一份优异的成绩单，在竞争激烈的市场环境下，今年上半年，京能清洁能源的营收、净利润同比增速双双取得两位数增长，可以说“稳”中有进，前进动力十足。1、业务稳健增长，行业地位进一步巩固通过京能清洁能源发布的半年度业绩报告，可以发现在经营业绩稳健增长的同时，在多个业务维度均有不俗表现，并且得到持续优化。装机容量稳步提高，截至2021年6月30日，公司控股总装机容量为1,121.5万千瓦，同比增长14%，其中，风力发电业务板块新增装机容量34.9万千瓦，全部来自于自建项目。发电量呈现较大幅度的增长。截至2021年6月30日，公司控股总发电量为161.79亿千瓦时，同比增长17.73%。其中燃气发电及供热业务板块发电量同比增长8.08%；风力发电业务板块发电量同比增长44.43%；光伏发电业务板块发电量同比增长37.87%，明显高于全国行业同期水平。总结来说，整个2021年上半年，京能清洁能源凭借其自身的软硬实力，充分发挥多元化的竞争优势，使得各个业务板块实现稳健增长。尤其是光伏板块更是超过全国同期的水平，充分迎合“30,60”、“碳达峰、碳中和”的发展理念，进一步巩固了公司作为地方新能源国企的行业领先地位。2、自主开发与项目并购双轮驱动，业务协同效应凸显评判一家企业的增长，往往有两个看点值得关注，其一，内生动力的增长，即依靠企业自身积累，厚积薄发；其二，外延式并购，通过收并购，实现市场、资源、技术的整合，在高效的企业内控能力之下，实现高速发展。 在内生动力增长方面，不断加快自主项目开发、建设的步伐。根据中报数据显示，截至2021年上半年，公司自主开发取得建设指标的风电、光伏项目18个，装机容量175.4万千瓦。 其中，公司承建的“京张奥运风电项目”，利用张家口地区丰富的风电资源，以北京市和河北省联合申办冬奥委会为契机，将张家口地区风电输送至北京电网以冬季供热方式进行消纳，同时为2022年北京冬奥委会在奥运史上首次实现全部场馆绿色电力覆盖的创举贡献首都国企的一份力量。不仅如此，该项目的建设让当地丰富的风能资源得到了开发与利用，对发展地区经济起到巨大的推动作用。同时极大地优化了北京能源结构，更有利于中央“京津冀一体化”协同发展的战略部署落地、产生实效。据了解，该项目总装机容量120万千瓦。其中京能清洁能源自建容量77.5万千瓦，截至目前，已经完成了东旭尚义20万千瓦风电项目、国新郝家营10万千瓦风电项目股转。京能清洁能源管理装机容量达107.5万千瓦，项目总投资约90亿元。在外延式扩张上，通过项目并购的方式大力拓展业务。截至2021年上半年，正在开展并购工作的风电、光伏项目共计13个，装机容量148.6万千瓦。今年7月份，公司与宁夏嘉泽订立了恺阳及博阳股权转让协议，收购了宁夏红寺堡297.5MW风电、光伏项目及宁夏同心99MW风电项目，为京能清洁能源下半年的装机容量增长贡献了一份力量。值得一提的是，此次收购有利于京能清洁能源西北分公司的集约化管理，将与公司既有资产形成较好的协同效应。不仅可以达到优势互补，取长补短，降本增效，业务相互协同的目的，还可以让公司形成全国化、全方位的战略布局。事实上，收购并购是新能源行业集中度增强的必经之路，也是行业内部洗牌的一种表现。随着整体行业自建项目成本的增加，寻求通过并购形式收购股权获得项目，甚至收购其他行业填补业态布局短板、扩大规模已成为新能源企业新的经营模式之一。对新能源企业而言，由之前的纯竞争转为合作，不仅可以相互借力，一定程度上规避投资风险，实现利益最大化。同时，还可以发挥各家所长，把企业做到最好。因此，长期来看，随着市场环境的变化，新能源企业未来的发展模式，除了苦练内功，增强自身的硬核实力之外，以并购、重组等形式来获取更多资源，多领域的尝试，“双轮驱动”以至“四轮驱动”将是新能源的企业未来成长之路，京能清洁能源已正式踏上了这条“做强、做大”的高速之路。","news_type":1,"symbols_score_info":{"00579":1}},"isVote":1,"tweetType":1,"viewCount":3946,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811109949,"gmtCreate":1630293486281,"gmtModify":1676530259693,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811109949","repostId":"1167910924","repostType":2,"repost":{"id":"1167910924","kind":"news","pubTimestamp":1630284735,"share":"https://ttm.financial/m/news/1167910924?lang=en_US&edition=fundamental","pubTime":"2021-08-30 08:52","market":"hk","language":"zh","title":"Why did Haidilao target Zhang Yong's wife and founder?","url":"https://stock-news.laohu8.com/highlight/detail?id=1167910924","media":"联商网资讯","summary":"这些年，作为火锅界的大哥，海底捞的日子过得并不太顺利。\n6月15日，在股东大会上，有人问，海底捞能否持续增长？董事长张勇耿直地回答：“大家神话海底捞了，我本人非常反感。我作为海底捞最大的股东，我是不抱","content":"<p>Over the years, as a leader in the hot pot industry,<a href=\"https://laohu8.com/S/06862\">Haidilao</a>Life wasn't going very smoothly.</p><p>On June 15, at the shareholders' meeting, someone asked whether Haidilao could continue to grow. Chairman Zhang Yong answered frankly: \"Everyone has mythologized Haidilao, which I personally find very offensive. As Haidilao's largest shareholder, I have no hope.\"</p><p>Zhang Yong said, \"I often say that if you want to know what it means to not live up to its name, just look at Haidilao. We face the same difficulties that all catering companies face; we still haven't solved the problems that all catering companies can't solve.\"</p><p>What Zhang Yong said was the truth and reliability. Of course, it cannot be ruled out that it was paving the way for Haidilao's declining performance and serving as a precaution. Investors should be mentally prepared.</p><p><b>01</b></p><p><b>Personnel changes</b></p><p><b>The team introduced fresh blood</b></p><p>On August 24, Haidilao announced that, effective immediately, Shu Ping had resigned as a non-executive director and member of the audit committee, and Shi Yonghong had resigned as an executive director. Both are the founders of Haidilao, and Shu Ping is the wife of Chairman Zhang Yong.</p><p>Haidilao stated that Shu Ping's resignation was due to an internal organizational restructuring, while Shi Yonghong's was to devote more time and energy to other businesses. Shu Ping became a director of the company in 2015 and was re-designated as a non-executive director in 2018, primarily responsible for overseeing the group's management and strategic development.</p><p>Shi Yonghong is the second-in-command of Haidilao and one of its founders. He became a director of the company in 2015 and was re-designated as an executive director in 2018, primarily responsible for participating in and overseeing the group's management and strategic development. In addition to working for the group, Shi Yonghong is also a hot pot ingredient supplier under Haidilao.<a href=\"https://laohu8.com/S/01579\">Yihai International</a>He is the executive director and chairman of Haidilao and holds director positions in several member companies of Haidilao.</p><p>The announcement also stated that Yang Lijuan has been appointed as the company's deputy CEO, and Cai Xinmin has been appointed as a member of the company's audit committee. Seven new executive directors, Yang Lijuan, Li Peng, Yang Hua, Liu Linyi, Li Yu, Song Qing, and Yang Li, and two new independent non-executive directors, Ma Weihua and Wu Xiaoguang, were added.</p><p>Prior to this appointment, Yang Lijuan was Haidilao's Chief Operating Officer, primarily responsible for overseeing the group's operations. Following this appointment, Yang Lijuan will be responsible for assisting the CEO in managing the group's overall operations.</p><p>In the first half of this year, Haidilao changed its organizational structure, changing the regional coordination coaching model to a large and community management model. Existing stores will be divided into five regions by geographical area, with regional managers coordinating store expansion, engineering, product selection, pricing, and other work within the region. Each district is divided into several communities, and community managers conduct on-site inspections, assessments, and guidance of stores within the area.</p><p>Haidilao stated that it hopes to accurately identify the problems existing in each store through organizational restructuring and provide continuous supervision and guidance.</p><p>According to reports, the new executive directors are all around 40 years old, most of whom were trained by Haidilao from the grassroots level and have rich front-line work experience. Yang Lijuan started her business with Zhang Yong in 1997 and was the first waitress Zhang Yong poached. After Haidilao went public, Yang Lijuan became the \"top waitress,\" holding 179 million shares of the company and a net worth of over 5 billion yuan.</p><p>In 1994, Shi Yonghong and his wife Li Haiyan co-founded Haidilao with Zhang Yong and his wife. Ten years later, Zhang Yong had his wife and Shi Yonghong resign from Haidilao's board of directors. The company also acquired the 18% stake in Haidilao held by Shi Yonghong and his wife at the original investment price.</p><p>In my opinion,<b>As the head of Haidilao, Zhang Yong's decision to have his wife and veteran founders step down from the front lines of management is a necessary means of organizational reform for Haidilao. On the one hand, it further downplays the aspect of family management; On the other hand, bringing fresh blood into the top management means the beginning of change.</b></p><p><b>02</b></p><p><b>Crazy expansion</b></p><p><b>What should I pay attention to at Haidilao?</b></p><p>On the evening of August 24, Haidilao released its 2021 semi-annual report. In the first half of the year, the company achieved revenue of 20.094 billion yuan, a year-on-year increase of 105.9%; The company achieved a net profit of 94.529 million yuan, compared to a loss of 965 million yuan in the same period last year, turning a loss into a profit.</p><p>Since February of this year, Haidilao's stock price has been declining steadily, falling by more than 60% compared to its peak. As of the market close on August 25, the company's share price was HK$27.4 per share, with a total market capitalization of HK$149.6 billion. In February of this year, Haidilao's stock price hit a record high of HK$85.8 per share, with a market capitalization of over HK$450 billion.<b>In just six months, more than HK$300 billion evaporated.</b></p><p>Why did the stock price fall? In my opinion, the pandemic, the biggest \"black swan\" event, has had a huge impact on the catering industry. With the pandemic recurring, the capital market is generally pessimistic about industries such as catering, entertainment, and cinema chains, making a decline in stock prices inevitable.</p><p>Since 2020, although the pandemic has had an adverse impact, Haidilao has seized the opportunity to expand against the trend.</p><p><img src=\"https://static.tigerbbs.com/f59b1a42861728038e42b70f76b76f58\" tg-width=\"660\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p><p>By 2019, Haidilao had a total of 768 stores, but in 2020 alone, Haidilao opened 530 new stores. Haidilao's expansion accelerated in the second half of 2020. Among the newly opened stores, 363 were added in the second half of 2020 and 299 were added in the first half of this year. According to media reports, the property management company offered many discounts after the pandemic, and the contract signing was more convenient, which made Haidilao tempted. Especially in third- and fourth-tier cities, local shopping malls offer preferential policies similar to rent-free, resulting in lower opening costs.</p><p>In order to improve performance and couple with the impact of increased costs caused by the pandemic, Haidilao quietly raised prices in April 2020. Some consumers discovered that a serving of freshly fried crispy pork had risen from 28 yuan to 44 yuan. Under public criticism, Haidilao quickly apologized and stated that it would restore the original price. In March of this year, Haidilao replaced the beef cubes in its condiments with plant-based protein \"Flavor Companion,\" and the \"Haidilao Beef Cube Modifier\" has once again plunged it into a media storm.</p><p>In my opinion, expanding against the trend during the pandemic is a correct strategic choice, just like buying at the bottom of the stock market. However, the problem is that opening a store is not just about expanding the hardware; the most important thing is that the supporting facilities, including service, management, and operations, keep up. Many chain retail companies often ultimately fail due to \"rapid expansion\". In the process of expansion, it is necessary to pay attention to at least three core elements:</p><p><b>First, the talent pool.</b>Opening a new store requires a corresponding talent team for terminal stores, and when the density of stores in an area increases, the talent team from the group to regional management needs to be able to keep up.</p><p><b>Second, cost control.</b>Opening a store means a large investment of fixed costs, which is one aspect; On the other hand, if the customer acquisition capabilities of a new store cannot keep up after it opens, the daily operating costs (food waste) will quickly make the new store a \"burden\" for the entire group.</p><p><b>Third, site selection.</b>Rapid store openings and expansion, to some extent, mean that new stores are a mixed bag, with varying degrees of quality. For any chain retail format, location selection is crucial. The biggest taboo is that, from the headquarters' perspective, they often open many stores with unwise locations in order to achieve the number of stores they want to open (thinking they will be popular or should be popular).</p><p><b>03</b></p><p><b>Besides \"service\"</b></p><p><b>What else does Haidilao have?</b></p><p>In June of this year, Zhang Yong pointed out: \"Since its inception, Haidilao has not yet truly established a completely scientific system. For example, in terms of process-oriented operations, when the organization is large, there will be various levels, and each level may violate some rules during operation. Why was Haidilao's system so powerful that it was hyped up online before? Because it was masked by performance.\" And every time I say there's a problem, everyone says I'm being modest.</p><p>As is well known, Haidilao builds its core competitive advantage through service, thus distinguishing itself from other catering brands.</p><p>Over the past 27 years, has Haidilao's USP (Unique Selling Proposition) of \"winning through service\" become outdated? Has the public become aesthetically fatigued with Haidilao?</p><p>My experience is that Haidilao's service is indeed better than any other restaurant, such as kind reminders, handing out heated towels, and providing each person with a small bowl of beef soup. Perhaps Haidilao was criticized for \"excessive service\" in the past, but now it seems that Haidilao has optimized its entire service items and standards, making them more natural and humane.</p><p><img src=\"https://static.tigerbbs.com/a54591efb4c80b81122ed14842f8f5e8\" tg-width=\"660\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p><p>From an objective perspective, Haidilao's service was not excessive and indeed enhanced the overall consumer experience. However, users can accept the cancellation of these services.</p><p>As the leading brand in the hot pot industry, among Sichuan-style hot pot...<b>From the perspectives of its dishes, cost-effectiveness, and taste, Haidilao doesn't seem to be the best.</b>Alternatively, it can be interpreted this way: Haidilao has established a distinction between itself and other Sichuan-style hot pot restaurants through \"service,\" and this distinction has led Haidilao to consciously raise its prices. Therefore, it has established its status as the \"hot pot king\" through \"high-quality service + high prices.\"</p><p>Under this positioning strategy, Haidilao avoided falling into competition with its peers in terms of products. For example, the side dishes in Haidilao's base pot are far inferior to those in Tan Ya Xue, and the dishes—including the main meats, tripe, and soy products—are far inferior to other Sichuan-style hot pots at the same price point. During my time in Chengdu this year, locals generally reported that very few people in Sichuan eat at Haidilao.</p><p>In summary, Haidilao's products themselves do not have a competitive advantage, and on the basis of the same quality, Haidilao's prices are far higher. Haidilao still manages to maintain a good popularity, but it carries the high title of the number one hot pot brand in vain, making it completely unattractive to seasoned foodies.</p><p>For categories like hot pot, deliciousness is naturally the primary factor. I believe Haidilao's consumer motivations fall into two categories:</p><p><b>The first category is trying something new.</b>Go and experience what Haidilao's service is really like.</p><p><b>The second category is the psychology of saving face.</b>。 When the boss brings company employees to gatherings, friends gatherings, birthday celebrations, etc., the prices at Haidilao are acceptable and respectable compared to five-star restaurants.</p><p><b>04</b></p><p><b>Retail Tendency of Catering Enterprises</b></p><p>Haidilao's 2021 semi-annual report also showed two key indicators:</p><p>Haidilao's once-proud table turnover rate has dropped to 3 times per day, which is lower than during the 2020 pandemic. In the first half of 2020, Haidilao's table turnover rate was 3.3 times per day, compared to an average table turnover rate of 3.5 times per day in 2020. Going back further, from 2016 to 2019, Haidilao's table turnover rates were 4.5 times/day, 5.0 times/day, 5.0 times/day, and 4.8 times/day, respectively.</p><p>Haidilao's average customer spending is also declining. In the first half of 2021, Haidilao's average customer spending was 107.3 yuan, compared to 112.8 yuan in the same period of the previous year.</p><p>Data shows that revenue, average order value per person, and table turnover rate are closely related, so the higher the data, the better. However, some industry insiders believe that the catering industry must \"reduce dine-in\" on the road to standardization, encourage takeout, and transform catering businesses into retail enterprises like supermarkets and department stores.</p><p>A 2017 article titled \"Why is Haidilao said to have led the catering industry astray?\" cited...<a href=\"https://laohu8.com/S/MCD\">McDonald's</a>As an example, the article asks: Why is it so difficult to operate in the Chinese catering industry, but McDonald's in the United States has maintained a market value of $100 billion for so many years? I was thinking, since China talks about table turnover rate, could McDonald's have other things besides table turnover rate?</p><p>I thought of scenes in movies where foreigners eat hamburgers, either carrying hamburgers on the street or grabbing something to eat while working overtime. So I asked someone to inquire about McDonald's takeout data. I found that McDonald's takeout data exceeds dine-in data, which means it is a retail industry.</p><p>In my opinion, fast food companies like McDonald's have very limited SKUs, making standardization very convenient. However, for relatively complex restaurants like hot pot (of course, stir-fried food products are even more complex), standardization is not easy, and the possibility of takeout is very low.</p><p>Therefore, it is almost impossible for Chinese restaurants to transform from a catering company into a \"retail company\" like McDonald's (although Haidilao has also launched takeout products such as self-service hot pot, its overall scale is still too small).</p><p><img src=\"https://static.tigerbbs.com/b3fa4873ced5aa075375268cb0520cd9\" tg-width=\"660\" tg-height=\"452\" referrerpolicy=\"no-referrer\"></p><p>So what does the decrease in average order value and table turnover rate mean for Haidilao? My understanding is as follows:</p><p><b>First, the decrease in average order value is not necessarily a bad thing for Haidilao.</b>When Haidilao's \"service\" is no longer absolutely attractive, its high prices will give many competitors an opportunity to take advantage of it. By bringing prices back to a rational level, Haidilao has a comparative advantage, and with the support of its brand power, it can actually attract more consumers.</p><p><b>Second, table turnover rates vary across different restaurant categories.</b>(The table turnover rate of Shaxian snacks is completely different from that of Haidilao), and the table turnover rate does not reflect the strength of the business capabilities (a high table turnover rate does not mean higher revenue per order). To some extent, a longer consumption time may also mean more consumption. Therefore, the table turnover rate indicator has two sides, and the table turnover rate is completely beyond the control of the merchant.</p><p>Finally, in my opinion, Haidilao has been around for 27 years, and the market's sense of novelty has greatly diminished.<b>Product innovation and business model innovation have reached a turning point that must be changed.</b></p>","source":"lsy1614676822040","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why did Haidilao target Zhang Yong's wife and founder?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy did Haidilao target Zhang Yong's wife and founder?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">联商网资讯</strong><span class=\"h-time small\">2021-08-30 08:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Over the years, as a leader in the hot pot industry,<a href=\"https://laohu8.com/S/06862\">Haidilao</a>Life wasn't going very smoothly.</p><p>On June 15, at the shareholders' meeting, someone asked whether Haidilao could continue to grow. Chairman Zhang Yong answered frankly: \"Everyone has mythologized Haidilao, which I personally find very offensive. As Haidilao's largest shareholder, I have no hope.\"</p><p>Zhang Yong said, \"I often say that if you want to know what it means to not live up to its name, just look at Haidilao. We face the same difficulties that all catering companies face; we still haven't solved the problems that all catering companies can't solve.\"</p><p>What Zhang Yong said was the truth and reliability. Of course, it cannot be ruled out that it was paving the way for Haidilao's declining performance and serving as a precaution. Investors should be mentally prepared.</p><p><b>01</b></p><p><b>Personnel changes</b></p><p><b>The team introduced fresh blood</b></p><p>On August 24, Haidilao announced that, effective immediately, Shu Ping had resigned as a non-executive director and member of the audit committee, and Shi Yonghong had resigned as an executive director. Both are the founders of Haidilao, and Shu Ping is the wife of Chairman Zhang Yong.</p><p>Haidilao stated that Shu Ping's resignation was due to an internal organizational restructuring, while Shi Yonghong's was to devote more time and energy to other businesses. Shu Ping became a director of the company in 2015 and was re-designated as a non-executive director in 2018, primarily responsible for overseeing the group's management and strategic development.</p><p>Shi Yonghong is the second-in-command of Haidilao and one of its founders. He became a director of the company in 2015 and was re-designated as an executive director in 2018, primarily responsible for participating in and overseeing the group's management and strategic development. In addition to working for the group, Shi Yonghong is also a hot pot ingredient supplier under Haidilao.<a href=\"https://laohu8.com/S/01579\">Yihai International</a>He is the executive director and chairman of Haidilao and holds director positions in several member companies of Haidilao.</p><p>The announcement also stated that Yang Lijuan has been appointed as the company's deputy CEO, and Cai Xinmin has been appointed as a member of the company's audit committee. Seven new executive directors, Yang Lijuan, Li Peng, Yang Hua, Liu Linyi, Li Yu, Song Qing, and Yang Li, and two new independent non-executive directors, Ma Weihua and Wu Xiaoguang, were added.</p><p>Prior to this appointment, Yang Lijuan was Haidilao's Chief Operating Officer, primarily responsible for overseeing the group's operations. Following this appointment, Yang Lijuan will be responsible for assisting the CEO in managing the group's overall operations.</p><p>In the first half of this year, Haidilao changed its organizational structure, changing the regional coordination coaching model to a large and community management model. Existing stores will be divided into five regions by geographical area, with regional managers coordinating store expansion, engineering, product selection, pricing, and other work within the region. Each district is divided into several communities, and community managers conduct on-site inspections, assessments, and guidance of stores within the area.</p><p>Haidilao stated that it hopes to accurately identify the problems existing in each store through organizational restructuring and provide continuous supervision and guidance.</p><p>According to reports, the new executive directors are all around 40 years old, most of whom were trained by Haidilao from the grassroots level and have rich front-line work experience. Yang Lijuan started her business with Zhang Yong in 1997 and was the first waitress Zhang Yong poached. After Haidilao went public, Yang Lijuan became the \"top waitress,\" holding 179 million shares of the company and a net worth of over 5 billion yuan.</p><p>In 1994, Shi Yonghong and his wife Li Haiyan co-founded Haidilao with Zhang Yong and his wife. Ten years later, Zhang Yong had his wife and Shi Yonghong resign from Haidilao's board of directors. The company also acquired the 18% stake in Haidilao held by Shi Yonghong and his wife at the original investment price.</p><p>In my opinion,<b>As the head of Haidilao, Zhang Yong's decision to have his wife and veteran founders step down from the front lines of management is a necessary means of organizational reform for Haidilao. On the one hand, it further downplays the aspect of family management; On the other hand, bringing fresh blood into the top management means the beginning of change.</b></p><p><b>02</b></p><p><b>Crazy expansion</b></p><p><b>What should I pay attention to at Haidilao?</b></p><p>On the evening of August 24, Haidilao released its 2021 semi-annual report. In the first half of the year, the company achieved revenue of 20.094 billion yuan, a year-on-year increase of 105.9%; The company achieved a net profit of 94.529 million yuan, compared to a loss of 965 million yuan in the same period last year, turning a loss into a profit.</p><p>Since February of this year, Haidilao's stock price has been declining steadily, falling by more than 60% compared to its peak. As of the market close on August 25, the company's share price was HK$27.4 per share, with a total market capitalization of HK$149.6 billion. In February of this year, Haidilao's stock price hit a record high of HK$85.8 per share, with a market capitalization of over HK$450 billion.<b>In just six months, more than HK$300 billion evaporated.</b></p><p>Why did the stock price fall? In my opinion, the pandemic, the biggest \"black swan\" event, has had a huge impact on the catering industry. With the pandemic recurring, the capital market is generally pessimistic about industries such as catering, entertainment, and cinema chains, making a decline in stock prices inevitable.</p><p>Since 2020, although the pandemic has had an adverse impact, Haidilao has seized the opportunity to expand against the trend.</p><p><img src=\"https://static.tigerbbs.com/f59b1a42861728038e42b70f76b76f58\" tg-width=\"660\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p><p>By 2019, Haidilao had a total of 768 stores, but in 2020 alone, Haidilao opened 530 new stores. Haidilao's expansion accelerated in the second half of 2020. Among the newly opened stores, 363 were added in the second half of 2020 and 299 were added in the first half of this year. According to media reports, the property management company offered many discounts after the pandemic, and the contract signing was more convenient, which made Haidilao tempted. Especially in third- and fourth-tier cities, local shopping malls offer preferential policies similar to rent-free, resulting in lower opening costs.</p><p>In order to improve performance and couple with the impact of increased costs caused by the pandemic, Haidilao quietly raised prices in April 2020. Some consumers discovered that a serving of freshly fried crispy pork had risen from 28 yuan to 44 yuan. Under public criticism, Haidilao quickly apologized and stated that it would restore the original price. In March of this year, Haidilao replaced the beef cubes in its condiments with plant-based protein \"Flavor Companion,\" and the \"Haidilao Beef Cube Modifier\" has once again plunged it into a media storm.</p><p>In my opinion, expanding against the trend during the pandemic is a correct strategic choice, just like buying at the bottom of the stock market. However, the problem is that opening a store is not just about expanding the hardware; the most important thing is that the supporting facilities, including service, management, and operations, keep up. Many chain retail companies often ultimately fail due to \"rapid expansion\". In the process of expansion, it is necessary to pay attention to at least three core elements:</p><p><b>First, the talent pool.</b>Opening a new store requires a corresponding talent team for terminal stores, and when the density of stores in an area increases, the talent team from the group to regional management needs to be able to keep up.</p><p><b>Second, cost control.</b>Opening a store means a large investment of fixed costs, which is one aspect; On the other hand, if the customer acquisition capabilities of a new store cannot keep up after it opens, the daily operating costs (food waste) will quickly make the new store a \"burden\" for the entire group.</p><p><b>Third, site selection.</b>Rapid store openings and expansion, to some extent, mean that new stores are a mixed bag, with varying degrees of quality. For any chain retail format, location selection is crucial. The biggest taboo is that, from the headquarters' perspective, they often open many stores with unwise locations in order to achieve the number of stores they want to open (thinking they will be popular or should be popular).</p><p><b>03</b></p><p><b>Besides \"service\"</b></p><p><b>What else does Haidilao have?</b></p><p>In June of this year, Zhang Yong pointed out: \"Since its inception, Haidilao has not yet truly established a completely scientific system. For example, in terms of process-oriented operations, when the organization is large, there will be various levels, and each level may violate some rules during operation. Why was Haidilao's system so powerful that it was hyped up online before? Because it was masked by performance.\" And every time I say there's a problem, everyone says I'm being modest.</p><p>As is well known, Haidilao builds its core competitive advantage through service, thus distinguishing itself from other catering brands.</p><p>Over the past 27 years, has Haidilao's USP (Unique Selling Proposition) of \"winning through service\" become outdated? Has the public become aesthetically fatigued with Haidilao?</p><p>My experience is that Haidilao's service is indeed better than any other restaurant, such as kind reminders, handing out heated towels, and providing each person with a small bowl of beef soup. Perhaps Haidilao was criticized for \"excessive service\" in the past, but now it seems that Haidilao has optimized its entire service items and standards, making them more natural and humane.</p><p><img src=\"https://static.tigerbbs.com/a54591efb4c80b81122ed14842f8f5e8\" tg-width=\"660\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p><p>From an objective perspective, Haidilao's service was not excessive and indeed enhanced the overall consumer experience. However, users can accept the cancellation of these services.</p><p>As the leading brand in the hot pot industry, among Sichuan-style hot pot...<b>From the perspectives of its dishes, cost-effectiveness, and taste, Haidilao doesn't seem to be the best.</b>Alternatively, it can be interpreted this way: Haidilao has established a distinction between itself and other Sichuan-style hot pot restaurants through \"service,\" and this distinction has led Haidilao to consciously raise its prices. Therefore, it has established its status as the \"hot pot king\" through \"high-quality service + high prices.\"</p><p>Under this positioning strategy, Haidilao avoided falling into competition with its peers in terms of products. For example, the side dishes in Haidilao's base pot are far inferior to those in Tan Ya Xue, and the dishes—including the main meats, tripe, and soy products—are far inferior to other Sichuan-style hot pots at the same price point. During my time in Chengdu this year, locals generally reported that very few people in Sichuan eat at Haidilao.</p><p>In summary, Haidilao's products themselves do not have a competitive advantage, and on the basis of the same quality, Haidilao's prices are far higher. Haidilao still manages to maintain a good popularity, but it carries the high title of the number one hot pot brand in vain, making it completely unattractive to seasoned foodies.</p><p>For categories like hot pot, deliciousness is naturally the primary factor. I believe Haidilao's consumer motivations fall into two categories:</p><p><b>The first category is trying something new.</b>Go and experience what Haidilao's service is really like.</p><p><b>The second category is the psychology of saving face.</b>。 When the boss brings company employees to gatherings, friends gatherings, birthday celebrations, etc., the prices at Haidilao are acceptable and respectable compared to five-star restaurants.</p><p><b>04</b></p><p><b>Retail Tendency of Catering Enterprises</b></p><p>Haidilao's 2021 semi-annual report also showed two key indicators:</p><p>Haidilao's once-proud table turnover rate has dropped to 3 times per day, which is lower than during the 2020 pandemic. In the first half of 2020, Haidilao's table turnover rate was 3.3 times per day, compared to an average table turnover rate of 3.5 times per day in 2020. Going back further, from 2016 to 2019, Haidilao's table turnover rates were 4.5 times/day, 5.0 times/day, 5.0 times/day, and 4.8 times/day, respectively.</p><p>Haidilao's average customer spending is also declining. In the first half of 2021, Haidilao's average customer spending was 107.3 yuan, compared to 112.8 yuan in the same period of the previous year.</p><p>Data shows that revenue, average order value per person, and table turnover rate are closely related, so the higher the data, the better. However, some industry insiders believe that the catering industry must \"reduce dine-in\" on the road to standardization, encourage takeout, and transform catering businesses into retail enterprises like supermarkets and department stores.</p><p>A 2017 article titled \"Why is Haidilao said to have led the catering industry astray?\" cited...<a href=\"https://laohu8.com/S/MCD\">McDonald's</a>As an example, the article asks: Why is it so difficult to operate in the Chinese catering industry, but McDonald's in the United States has maintained a market value of $100 billion for so many years? I was thinking, since China talks about table turnover rate, could McDonald's have other things besides table turnover rate?</p><p>I thought of scenes in movies where foreigners eat hamburgers, either carrying hamburgers on the street or grabbing something to eat while working overtime. So I asked someone to inquire about McDonald's takeout data. I found that McDonald's takeout data exceeds dine-in data, which means it is a retail industry.</p><p>In my opinion, fast food companies like McDonald's have very limited SKUs, making standardization very convenient. However, for relatively complex restaurants like hot pot (of course, stir-fried food products are even more complex), standardization is not easy, and the possibility of takeout is very low.</p><p>Therefore, it is almost impossible for Chinese restaurants to transform from a catering company into a \"retail company\" like McDonald's (although Haidilao has also launched takeout products such as self-service hot pot, its overall scale is still too small).</p><p><img src=\"https://static.tigerbbs.com/b3fa4873ced5aa075375268cb0520cd9\" tg-width=\"660\" tg-height=\"452\" referrerpolicy=\"no-referrer\"></p><p>So what does the decrease in average order value and table turnover rate mean for Haidilao? My understanding is as follows:</p><p><b>First, the decrease in average order value is not necessarily a bad thing for Haidilao.</b>When Haidilao's \"service\" is no longer absolutely attractive, its high prices will give many competitors an opportunity to take advantage of it. By bringing prices back to a rational level, Haidilao has a comparative advantage, and with the support of its brand power, it can actually attract more consumers.</p><p><b>Second, table turnover rates vary across different restaurant categories.</b>(The table turnover rate of Shaxian snacks is completely different from that of Haidilao), and the table turnover rate does not reflect the strength of the business capabilities (a high table turnover rate does not mean higher revenue per order). To some extent, a longer consumption time may also mean more consumption. Therefore, the table turnover rate indicator has two sides, and the table turnover rate is completely beyond the control of the merchant.</p><p>Finally, in my opinion, Haidilao has been around for 27 years, and the market's sense of novelty has greatly diminished.<b>Product innovation and business model innovation have reached a turning point that must be changed.</b></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://mp.weixin.qq.com/s/l7-nK7ZKXP7kndgoByHglQ\">联商网资讯</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/23f2c25e060d113f3768c45cafc16292","relate_stocks":{"06862":"海底捞","09988":"阿里巴巴-W"},"source_url":"https://mp.weixin.qq.com/s/l7-nK7ZKXP7kndgoByHglQ","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167910924","content_text":"这些年，作为火锅界的大哥，海底捞的日子过得并不太顺利。\n6月15日，在股东大会上，有人问，海底捞能否持续增长？董事长张勇耿直地回答：“大家神话海底捞了，我本人非常反感。我作为海底捞最大的股东，我是不抱有希望的。”\n张勇说，“我常常讲，要想知道什么是名不符实，看看海底捞就知道了，所有餐饮企业面临的困难，我们同样面临；所有餐饮企业不能解决的问题，我们依然没有解决。”\n张勇所说的是真实靠谱的大实话，当然，也不排除为海底捞的业绩下滑做铺垫，打预防针，对投资人来说，要有个心理准备。\n01\n人事变动\n团队引入新鲜血液\n8月24日，海底捞宣布，自即日起，舒萍辞任公司非执行董事及审计委员会成员，施永宏辞任公司执行董事。这两人都是海底捞的创始人，舒萍是董事长张勇的妻子。\n海底捞表示，舒萍辞任的原因是公司内部组织架构调整，而施永宏则是为了将更多的时间和精力投入到其他业务中。舒萍于2015年成为公司董事，并于2018年调任非执行董事，主要负责监督集团的管理与战略发展。\n施永宏是海底捞的“二把手”，也是创始人之一。其于2015年成为公司董事，并于2018年调任执行董事，主要负责参与并监督集团的管理以及战略发展。除了在集团任职外，施永宏还是海底捞旗下火锅料供应商颐海国际的执行董事及董事长，并在海底捞旗下多个成员公司担任董事职位。\n公告同时表示，杨利娟被任为公司副首席执行官，蔡新民被任为公司审计委员会成员。并新增杨利娟、李朋、杨华、刘林毅、李瑜、宋青、杨立七位执行董事，新增马蔚华、吴宵光两位独立非执行董事。\n杨利娟在此次任命前是海底捞的首席营运官，主要负责监督集团的运营工作。此次任命后，杨利娟将负责协助首席执行官管理集团整体运营工作。\n今年上半年，海底捞变更组织构架，将区域统筹教练模式，改为大、小区管理模式。将现有门店按地域划分为5个大区，由大区经理统筹区域内的门店拓展、工程、选品、定价等工作。每个大区分设若干小区，由小区经理对区域内门店进行现场巡视、考核和辅导。\n海底捞表示，希望通过组织构架的变革，精准识别每家门店存在的问题，并进行持续性的监督和辅导。\n据报道，新的执行董事，年龄都在40岁上下，大多是海底捞从基层培养出来的，有丰富的一线工作经验。杨利娟从1997年起，就跟随张勇一起创业，是张勇挖来的首个服务员。海底捞上市后，杨利娟成为了“最牛服务员”，持有公司1.79亿股，身价超过50亿元。\n1994年，施永宏和妻子李海燕与张勇夫妇共同创立了海底捞。十年后，张勇让妻子和施永宏退出海底捞董事会。并以原始出资价格收购施永宏夫妇所持海底捞18%股权。\n笔者以为，作为海底捞的掌门人，张勇让妻子和元老级创始人一起退出管理一线，对海底捞来说，是组织革新的必要手段。一方面，进一步淡化家族管理的色彩；另一方面，让新鲜血液进入最高管理层，意味着变革的开始。\n02\n疯狂扩张\n海底捞需要注意什么？\n8月24日晚间，海底捞发布2021年半年报。上半年，公司实现营收200.94亿元，同比增长105.9％；实现净利润9452.9万元，较上年同期的亏损9.65亿元，实现扭亏为盈。\n从今年2月以后，海底捞的股价就一路向下，相比最高时，跌去了6成多。截至8月25日收盘，公司股价报27.4港元/股，总市值为1496亿港元。今年2月，海底捞股价创出历史新高，达85.8港元/股，市值超过4500亿港元。仅仅半年，就蒸发3000多亿港元。\n股价为什么下跌？笔者以为，疫情这个最大“黑天鹅”对餐饮行业造成巨大的影响。在疫情不断反反复复的状态之下，资本市场对餐饮、娱乐、院线等行业普遍不看好，股价下跌成为必然。\n从2020年至今，疫情虽然造成不利影响，但海底捞却抓住机会，逆势扩张。\n\n到2019年海底捞共有768家店，但2020年一年，海底捞就新开了530家店。海底捞的扩张提速始于2020年下半年，在新开门店当中，2020年下半年新增363家，今年上半年新增299家。据媒体报道，疫情之后物业给了很多优惠，签约有更高的便利度，这让海底捞无法不心动。尤其在三四线城市，当地商场会提供类似免租的优惠政策，开店成本更低。\n为了提升业绩加之疫情导致的成本提升的影响，2020年4月海底捞悄悄涨价。有消费者发现一份现炸酥肉由28元涨至44元，在舆论的“口诛笔伐”下，海底捞很快致歉并表示恢复原价。今年3月，海底捞将小料中的牛肉粒以植物蛋白“味伴侣”替代，“海底捞牛肉粒变素”让它再次陷入舆论漩涡。\n笔者认为，在疫情期间逆势扩张，是一个正确的战略选择，就跟股市抄底的道理一样。但问题是，开店并不仅仅是在硬件的扩张，服务、管理、营运这一系列的配套跟得上才是最重要的。很多连锁型零售企业，往往最终兵败“快速扩张”。在扩张的过程中，至少需要关注最为核心的三点要素：\n第一、人才队伍。新开一个门店，对于终端门店来说需要相应的人才团队，而当在一个片区门店密度加大之后，从集团到区域化管理的人才队伍都需要能够跟得上。\n第二、成本控制。开店意味着大量的固定成本投入，这是一方面；另一方面，新店运营之后如果获客能力跟不上，日常的运营成本(菜品的损耗)会让新店迅速成为整个集团的“累赘”。\n第三、选址。快速的开店扩张，一定程度上意味着新店泥沙俱下，良莠不齐。对任何连锁零售业态来说，选址至关重要。最为忌讳的是，从总部的角度出发，往往会为了实现开店数量目标，而怀揣侥幸心理(以为能火爆、应该能火爆)地开出不少选址并不明智的门店。\n03\n除了“服务”\n海底捞还有什么？\n张勇在今年6月份曾指出：“海底捞从创业到目前为止，还没有真正建立过完全科学的制度。比如流程化操作方面，组织大了会有各种层级，每个层级在操作中都可能会违反一些制度。为什么之前网上炒作海底捞制度很牛逼？因为被业绩给掩盖了。而且我每次说有问题，大家都说我是谦虚。”\n众所周知，海底捞是以服务打造自己的核心竞争优势，从而区别于其他的餐饮品牌。\n二十七年来，海底捞这种“服务取胜”的USP(独特的销售主张Unique Selling Proposition)过时了吗？大众对海底捞是否已经审美疲劳？\n笔者的体验是，海底捞的服务确实比其他任何一家餐饮都好，比如说善意的提醒，递热毛巾，配好每人一份的小碗牛肉汤等等。也许在过去海底捞饱受“过度服务”的批判，目前来看，海底捞对整个服务项目和标准已经有所优化，更加自然和人性化。\n\n从客观的角度来评价，海底捞的服务没有过度，确实能够为全程的消费体验加分。但是，如果取消掉这些服务，用户也能接受。\n作为火锅赛道的第一品牌，在川派火锅当中，从菜品、性价比和口味三个角度来看，海底捞似乎都不是最佳的。或者可以这么解读，海底捞以“服务”建立了自己与其他川派火锅之间的区隔，而这样的区隔又让海底捞有意识地拉高了自己的定价，所以，以“优质服务+高价位”确立了海底捞“火锅一哥”的身份。\n在这样的定位策略之下，海底捞避免了在产品上陷入与同行的竞争。比如说底锅，海底捞底锅中的配菜远不如谭鸭血，而菜品——包括主打的肉类、毛肚、豆制品等，在同等价位之下远不如其他川派火锅。笔者今年在成都期间，当地人普遍反映，四川很少有人吃海底捞。\n综合分析来看，海底捞的产品本身并没有竞争优势，在同品质的基础上，海底捞的价格远远偏高。而海底捞依然尚能维持不错的热度，只是徒然带着火锅第一品牌的高帽子，对于资深吃货而言，海底捞丝毫没有吸引力。\n对于火锅这样的品类，好吃自然第一要素，海底捞的消费动机，笔者以为可能会有两类：\n第一类，尝鲜，去体验一下海底捞的服务到底是什么样的。\n第二类，面子心理。老板带公司员工聚会，或者朋友聚会，生日庆祝等，海底捞消费，相较于五星级饭店来说价位能接受，也有面子。\n04\n餐饮企业的零售化倾向\n海底捞发布的2021半年报还显示了两项关键指标：\n海底捞一直引以为傲的翻台率跌到了3次/天，比2020年疫情期间还低。2020年上半年，海底捞的翻台率为3.3次/天，2020年的平均翻台率为3.5次/天。再往前追溯，2016年-2019年，海底捞的翻台率分别为4.5次/天、5.0次/天、5.0次/天以及4.8次/天。\n海底捞的顾客人均消费也在下滑。2021年上半年，海底捞的顾客人均消费为107.3元，而上年同期为112.8元。\n从数据上看，营业额跟人均消费客单价跟翻台率紧密相关，数据自然是越高越好。但也有业内人士认为，餐饮在标准化的道路上，必须要实现“降低堂食”，鼓励外卖带走，让餐饮企业变成商超百货一样的零售企业。\n2017年的一篇文章《为什么说海底捞把餐饮行业给带到沟里去了？》举了麦当劳的例子，文章说：为什么中国餐饮这么难做，但是美国的麦当劳1000亿美金市值这么多年？我就思考，中国都讲翻台率，那麦当劳会不会除了翻台率还有其他的？\n我想到一些电影里老外吃汉堡的场景，要么是拎着汉堡在街上吃，要么是加班时候随手拿个吃，我就托人打听麦当劳的外带数据，我发现麦当劳外带的数据超过堂食数据，这代表它是零售业。\n笔者以为，麦当劳这样的快餐企业SKU非常有限，标准化非常方便，但是火锅这样相对比较复杂(当然炒菜类餐饮产品更复杂)的餐饮来说，标准化并不容易，而且外卖的可能性很低。\n所以，中餐企业想要类似麦当劳那样从餐饮企业变成“零售企业”，几乎很难(虽然海底捞也推出了自嗨锅这样的外卖产品，但整体规模毕竟太小了)。\n\n那么客单价和翻台率双双降低，对海底捞意味着什么呢？笔者的理解是这样的：\n第一，客单价的降低对海底捞来说并不一定就是坏事。当海底捞的“服务”不再具有绝对吸引力的时候，高价位会让众多竞争对手有机可乘。让价格回归理性，具有比较优势，在品牌势能的加持之下，海底捞反而可以吸引更多的消费者。\n第二，不同的餐饮品类翻台率各有不同(沙县小吃的翻台率跟海底捞完全不同)，而且翻台率的高低并不能反映经营能力的强弱(翻台率高不代表每一单的营业收入更高)，在某种程度上，消费时间长也可能意味着消费得更多，所以翻台率这个指标具有双面性，而且翻台率也完全不是商家所能控制的。\n最后，笔者以为，已经走过了27年的海底捞，市场对其新鲜体验感已经大大降低，产品创新，模式创新已经到了一个不得不改变的转折点。","news_type":1,"symbols_score_info":{"09988":0.9,"06862":0.9}},"isVote":1,"tweetType":1,"viewCount":3439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810814571,"gmtCreate":1629962150993,"gmtModify":1676530185284,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810814571","repostId":"2162106440","repostType":2,"repost":{"id":"2162106440","kind":"news","pubTimestamp":1629959831,"share":"https://ttm.financial/m/news/2162106440?lang=en_US&edition=fundamental","pubTime":"2021-08-26 14:37","market":"sh","language":"zh","title":"Morgan Stanley: Gives WuXi Biologics \"Overweight\" rating, raises target price 3.6% to HK$170","url":"https://stock-news.laohu8.com/highlight/detail?id=2162106440","media":"智通财经","summary":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。 ...","content":"<p><div>Morgan Stanley released a research report stating that it has given WuXi Biologics (02269) an \"overweight\" rating, raised its target price from HK$164 to HK$170, and raised its earnings forecast for 2021-24 by 1% to 9% to reflect strong first-half performance. Revenue and gross profit forecasts have also been raised accordingly. Follow Tonghuashun Finance (ths518) for more opportunities. Editor: cjh</p><p><a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">Web page link</a></div></p>","source":"tonghuashun","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley: Gives WuXi Biologics \"Overweight\" rating, raises target price 3.6% to HK$170</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley: Gives WuXi Biologics \"Overweight\" rating, raises target price 3.6% to HK$170\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-26 14:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div>Morgan Stanley released a research report stating that it has given WuXi Biologics (02269) an \"overweight\" rating, raised its target price from HK$164 to HK$170, and raised its earnings forecast for 2021-24 by 1% to 9% to reflect strong first-half performance. Revenue and gross profit forecasts have also been raised accordingly. Follow Tonghuashun Finance (ths518) for more opportunities. Editor: cjh</p><p><a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">Web page link</a></div></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16","relate_stocks":{"02269":"药明生物"},"source_url":"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","article_id":"2162106440","content_text":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。\n关注同花顺财经（ths518），获取更多机会\n\n责任编辑：cjh","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":3148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837654134,"gmtCreate":1629886521628,"gmtModify":1676530162487,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837654134","repostId":"2162031026","repostType":2,"repost":{"id":"2162031026","kind":"news","pubTimestamp":1629875170,"share":"https://ttm.financial/m/news/2162031026?lang=en_US&edition=fundamental","pubTime":"2021-08-25 15:06","market":"hk","language":"zh","title":"Zhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments","url":"https://stock-news.laohu8.com/highlight/detail?id=2162031026","media":"智通财经","summary":"智通财经APP获悉，中泰证券发布研究报告称，维持药明生物“买入”评级，认为公司是全球生物药外包服务行业稀缺标的，所处行业高景气、公司优势凸显，后续随着现有项目进入商业化，以及XDC、疫苗、双抗等平台加速兑现，长期空间广阔，未来可期。中泰证券主要观点如下：业绩超预期，归母净利润高于业绩预告。前次业绩预告2021H1归母净利润同比增长135%，实际增长150.3%，高于预期。","content":"<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/600918\">Zhongtai Securities</a>Released a research report saying that maintaining<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Buy\" rating, believing that the company is a scarce target in the global biopharmaceutical outsourcing service industry, with high prosperity in the industry and prominent advantages of the company. Subsequently, with the commercialization of existing projects, XDC, vaccines, double antibodies and other platforms to accelerate the realization, the long-term space is broad, and the future is promising.</p><p><strong>Event:</strong>The company released its results for the first half of 2021, and achieved operating income of 4.41 billion yuan during the period, representing a year-on-year increase of 126.7%; Net profit attributable to the parent was 1.84 billion yuan, a year-on-year increase of 150.3%; The adjusted net profit attributable to the parent was 1.77 billion yuan, a year-on-year increase of 163%.</p><p><strong>The main views of Zhongtai Securities are as follows:</strong></p><p><strong>The performance exceeded expectations, and the net profit attributable to the parent was higher than the performance forecast.</strong></p><p>The previous performance forecast 2021H1 net profit attributable to the parent increased by 135% year-on-year, and the actual growth was 150.3%, which was higher than expected. The Bank believes that it is mainly due to:</p><p>1) The volume of late clinical and commercialization projects increased rapidly, including the clinical stage revenue of 1.94 billion yuan (+109.2% year-on-year) and the commercialization stage revenue of 889 million yuan (+2923.5%);</p><p>2) the rapid recovery of demand after the normalization of overseas epidemic, with revenue from North America of RMB2.19 billion (+149.3% year-on-year) and revenue from Europe of RMB990 million (+706.8% year-on-year) in 2021H1;</p><p>3) continuous optimization of management capabilities and continuous improvement of operational efficiency, with gross profit margin of approximately 52.1% (+11.6pp), net profit margin of approximately 41.8% (+3.9pp) and period expense ratio of approximately 12.4% (-8.2pp) in 2021H1;</p><p>4) Low base last year: In the first half of last year, the overall base was low due to the epidemic disturbance, with 740 million (+63.6%) attributable to the parent in 2020H1. However, compared with the net profit attributable to the parent in 2019H1, the company's CAGR from 2019H1 to 2021H1 was about 102.3%, with a rapid growth.</p><p><strong>CMO's logic of heavy volume continues to be realized, and the strategy of following and winning molecules is progressing smoothly, which is expected to accelerate the growth of overall performance.</strong></p><p>Adhering to the strategy of following and winning molecules, as of June 30, the company extended 27 projects (14 pre-clinical to clinical, 2 phase III to commercial) in the first half of the year, introduced 20 clinical projects externally (+400%, including 9 clinical phase II and 4 clinical phase III), added 79 projects, and the overall number of projects reached 408 (+42.7% year-on-year compared with 2020H1), including 212 pre-clinical (+50.4%), 160 early (phase I and phase II) projects (+28%), 32 phase III projects (+68.4%), and 4 commercial projects (three new).</p><p>In addition, due to the rapid growth of the number of projects, the company's orders in hand continue to increase rapidly. It is expected that in the next three years, the total amount of orders completed will reach 2.25 billion USD (+143.1%), and the total amount of uncompleted orders will be about 12.46 billion USD (+31.7%), of which the outstanding service orders will be 7.23 billion USD (+25.2%). It is expected that the bank will have seven commercialization projects in 2021, which is expected to promote a new round of heavy volume in the CDMO sector and accelerate the overall performance growth.</p><p><strong>Advanced XDC, vaccine and dual antibody platforms bring new growth momentum.</strong></p><p><strong>XDC:</strong>The company's XDC drug R&D platform has undertaken 48 ADC projects (+60%) with the advantages of WuXiDAR4 technology, and 15 CDMO projects are already underway, and the commercialization volume can be expected;</p><p><strong>WuxiVaccine:</strong>Nine vaccine orders are being executed (up 8 year-on-year), and the orders in hand have increased to US$3.3 billion. WuXi Haide is expected to be put into operation in 2022, which is expected to continue to bring incremental performance.</p><p><strong>Double antibody:</strong>WuxiBody ™ Undertake 31 projects (+19.2%), and expect to add 1~2 IND applications in 2021, which is expected to extend CDMO to gradually contribute new increments.</p><p><strong>Earnings Forecast and Investment Advice:</strong>The bank estimates that the company's revenue from 2021 to 2023 will be 9.36, 13.84 and 19.4 billion yuan, representing a year-on-year increase of 66.7%, 47.9% and 40.2%, and the net profit attributable to the parent will be 2.82, 4.17 and 5.88 billion yuan, representing a year-on-year increase of 67.1%, 47.6% and 41.2%, corresponding to EPS of 0.67, 0.98 and 1.39 yuan.</p><p><strong>Risk warning events:</strong>The public information used in the research report may be subject to the risk of information lag or updating in a timely manner, proposed acquisition<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>The risks of the progress of China's biologics production base project being less than expected, the investment in biologics research and development being less than expected, and the risk of loss of core technical personnel.</p><p></body></html></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-25 15:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/600918\">Zhongtai Securities</a>Released a research report saying that maintaining<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Buy\" rating, believing that the company is a scarce target in the global biopharmaceutical outsourcing service industry, with high prosperity in the industry and prominent advantages of the company. Subsequently, with the commercialization of existing projects, XDC, vaccines, double antibodies and other platforms to accelerate the realization, the long-term space is broad, and the future is promising.</p><p><strong>Event:</strong>The company released its results for the first half of 2021, and achieved operating income of 4.41 billion yuan during the period, representing a year-on-year increase of 126.7%; Net profit attributable to the parent was 1.84 billion yuan, a year-on-year increase of 150.3%; The adjusted net profit attributable to the parent was 1.77 billion yuan, a year-on-year increase of 163%.</p><p><strong>The main views of Zhongtai Securities are as follows:</strong></p><p><strong>The performance exceeded expectations, and the net profit attributable to the parent was higher than the performance forecast.</strong></p><p>The previous performance forecast 2021H1 net profit attributable to the parent increased by 135% year-on-year, and the actual growth was 150.3%, which was higher than expected. The Bank believes that it is mainly due to:</p><p>1) The volume of late clinical and commercialization projects increased rapidly, including the clinical stage revenue of 1.94 billion yuan (+109.2% year-on-year) and the commercialization stage revenue of 889 million yuan (+2923.5%);</p><p>2) the rapid recovery of demand after the normalization of overseas epidemic, with revenue from North America of RMB2.19 billion (+149.3% year-on-year) and revenue from Europe of RMB990 million (+706.8% year-on-year) in 2021H1;</p><p>3) continuous optimization of management capabilities and continuous improvement of operational efficiency, with gross profit margin of approximately 52.1% (+11.6pp), net profit margin of approximately 41.8% (+3.9pp) and period expense ratio of approximately 12.4% (-8.2pp) in 2021H1;</p><p>4) Low base last year: In the first half of last year, the overall base was low due to the epidemic disturbance, with 740 million (+63.6%) attributable to the parent in 2020H1. However, compared with the net profit attributable to the parent in 2019H1, the company's CAGR from 2019H1 to 2021H1 was about 102.3%, with a rapid growth.</p><p><strong>CMO's logic of heavy volume continues to be realized, and the strategy of following and winning molecules is progressing smoothly, which is expected to accelerate the growth of overall performance.</strong></p><p>Adhering to the strategy of following and winning molecules, as of June 30, the company extended 27 projects (14 pre-clinical to clinical, 2 phase III to commercial) in the first half of the year, introduced 20 clinical projects externally (+400%, including 9 clinical phase II and 4 clinical phase III), added 79 projects, and the overall number of projects reached 408 (+42.7% year-on-year compared with 2020H1), including 212 pre-clinical (+50.4%), 160 early (phase I and phase II) projects (+28%), 32 phase III projects (+68.4%), and 4 commercial projects (three new).</p><p>In addition, due to the rapid growth of the number of projects, the company's orders in hand continue to increase rapidly. It is expected that in the next three years, the total amount of orders completed will reach 2.25 billion USD (+143.1%), and the total amount of uncompleted orders will be about 12.46 billion USD (+31.7%), of which the outstanding service orders will be 7.23 billion USD (+25.2%). It is expected that the bank will have seven commercialization projects in 2021, which is expected to promote a new round of heavy volume in the CDMO sector and accelerate the overall performance growth.</p><p><strong>Advanced XDC, vaccine and dual antibody platforms bring new growth momentum.</strong></p><p><strong>XDC:</strong>The company's XDC drug R&D platform has undertaken 48 ADC projects (+60%) with the advantages of WuXiDAR4 technology, and 15 CDMO projects are already underway, and the commercialization volume can be expected;</p><p><strong>WuxiVaccine:</strong>Nine vaccine orders are being executed (up 8 year-on-year), and the orders in hand have increased to US$3.3 billion. WuXi Haide is expected to be put into operation in 2022, which is expected to continue to bring incremental performance.</p><p><strong>Double antibody:</strong>WuxiBody ™ Undertake 31 projects (+19.2%), and expect to add 1~2 IND applications in 2021, which is expected to extend CDMO to gradually contribute new increments.</p><p><strong>Earnings Forecast and Investment Advice:</strong>The bank estimates that the company's revenue from 2021 to 2023 will be 9.36, 13.84 and 19.4 billion yuan, representing a year-on-year increase of 66.7%, 47.9% and 40.2%, and the net profit attributable to the parent will be 2.82, 4.17 and 5.88 billion yuan, representing a year-on-year increase of 67.1%, 47.6% and 41.2%, corresponding to EPS of 0.67, 0.98 and 1.39 yuan.</p><p><strong>Risk warning events:</strong>The public information used in the research report may be subject to the risk of information lag or updating in a timely manner, proposed acquisition<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>The risks of the progress of China's biologics production base project being less than expected, the investment in biologics research and development being less than expected, and the risk of loss of core technical personnel.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/543594.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{"600918":"中泰证券","02269":"药明生物"},"source_url":"http://www.zhitongcaijing.com/content/detail/543594.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162031026","content_text":"智通财经APP获悉，中泰证券发布研究报告称，维持药明生物(02269)“买入”评级，认为公司是全球生物药外包服务行业稀缺标的，所处行业高景气、公司优势凸显，后续随着现有项目进入商业化，以及XDC、疫苗、双抗等平台加速兑现，长期空间广阔，未来可期。事件：公司发布2021年上半年业绩，期内实现营业收入44.1亿元，同比增长126.7%;归母净利润18.4亿元，同比增长150.3%;经调整归母净利润17.7亿元，同比增长163%。中泰证券主要观点如下：业绩超预期，归母净利润高于业绩预告。前次业绩预告2021H1归母净利润同比增长135%，实际增长150.3%，高于预期。该行认为主要源于：1)临床后期及商业化项目快速放量，其中临床阶段收入19.4亿元(同比+109.2%)，商业化阶段收入8.89亿(+2923.5%);2)海外疫情常态化后需求的快速恢复，2021H1北美收入21.9亿元(同比+149.3%)，欧洲收入9.9亿元(同比+706.8%);3)管理能力持续优化，运营效率持续提升，2021H1毛利率约为52.1%(+11.6pp)，净利率约为41.8%(+3.9pp)，期间费用率约12.4%(-8.2pp);4)去年基数低：去年上半年因疫情扰动导致整体基数较低，2020H1归母7.4亿(+63.6%)，但对比2019H1归母净利润，公司2019H1-2021H1CAGR约102.3%，增长迅猛。CMO放量逻辑持续兑现，跟随并赢得分子策略进展顺利，有望带动整体业绩加速增长。公司秉承跟随及赢得分子策略，截止6月30日，上半年延伸27个项目(14个临床前至临床、2个III期至商业化)，外部引进20个临床项目(+400%，其中临床II期9个、临床III期4个)，新增79个项目，整体项目数达408个(较2020H1同比+42.7%)，其中临床前212个(+50.4%)、早期(I期、II期)项目数达160个(+28%)，III期项目达32个(+68.4%)，商业化项目4个(新增三个)。此外，源于项目数不断快速增长，公司在手订单持续高增，预计未来三年能够完成订单总额达22.5亿美元(+143.1%)，未完成订单总额约124.6亿美元(+31.7%)，其中未完成服务订单72.3亿美元(+25.2%)。该行预计2021年将有7个商业化项目落地，有望推动CDMO板块新一轮放量，带动整体业绩提速增长。先进的XDC、疫苗、双抗平台带来增长新动能。XDC：公司XDC药物研发平台凭借WuXiDAR4技术优势承接48个ADC项目(+60%)，已有15个CDMO项目正在进行，商业化放量可期;WuxiVaccine：9个疫苗订单正在执行(同比增长8个)，在手订单提升至33亿美元，药明海德预计2022年投入运营，有望持续带来业绩增量。双抗：WuxiBody™承接31个项目(+19.2%)，预计2021年新增1~2个IND申请，有望延伸CDMO逐步贡献新增量。盈利预测与投资建议：该行预计2021-2023年公司收入93.6、138.4和194亿元，同比增长66.7%、47.9%、40.2%，归母净利润28.2、41.7和58.8亿元，同比增长67.1%、47.6%、41.2%，对应EPS为0.67、0.98、1.39元。风险提示事件：研究报告使用的公开资料可能存在信息滞后或更新不及时的风险、拟收购辉瑞中国生物药生产基地项目进展不及预期风险、生物药研发投入不及预期、核心技术人员流失的风险。","news_type":1,"symbols_score_info":{"600918":1,"02269":1}},"isVote":1,"tweetType":1,"viewCount":4139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835151166,"gmtCreate":1629696705355,"gmtModify":1676530102959,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835151166","repostId":"2161725272","repostType":2,"repost":{"id":"2161725272","kind":"news","pubTimestamp":1629684392,"share":"https://ttm.financial/m/news/2161725272?lang=en_US&edition=fundamental","pubTime":"2021-08-23 10:06","market":"us","language":"zh","title":"[Stocks in Focus] WuXi Biologics (02269.HK) rose 3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2161725272","media":"金融界网站","summary":"【财华社讯】药明生物(02269.HK)截至10:06上涨3.13%，现报108.6港元，涨3.3港元。成交375万股，涉资3.967亿元。（出处：FinetAI）","content":"<p><html><body><div>[Caihua News Agency]<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269.HK) rose 3.13% as of 10:06 and is currently trading at HK$108.6, up HK$3.3. 3.75 million shares were traded, involving 396.7 million yuan. (Source: FinetAI)</p><p><div></div></div></body></html></p>","source":"jinrongjie_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[Stocks in Focus] WuXi Biologics (02269.HK) rose 3.13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[Stocks in Focus] WuXi Biologics (02269.HK) rose 3.13%\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">金融界网站</strong><span class=\"h-time small\">2021-08-23 10:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div>[Caihua News Agency]<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269.HK) rose 3.13% as of 10:06 and is currently trading at HK$108.6, up HK$3.3. 3.75 million shares were traded, involving 396.7 million yuan. (Source: FinetAI)</p><p><div></div></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://hk.jrj.com.cn/2021/08/23100633301119.shtml\">金融界网站</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","relate_stocks":{"02269":"药明生物"},"source_url":"http://hk.jrj.com.cn/2021/08/23100633301119.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161725272","content_text":"【财华社讯】药明生物(02269.HK)截至10:06上涨3.13%，现报108.6港元，涨3.3港元。成交375万股，涉资3.967亿元。（出处：FinetAI）","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":3913,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320086108,"gmtCreate":1614990798804,"gmtModify":1704777945890,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320086108","repostId":"1183532320","repostType":2,"repost":{"id":"1183532320","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614957526,"share":"https://ttm.financial/m/news/1183532320?lang=en_US&edition=fundamental","pubTime":"2021-03-05 23:18","market":"us","language":"zh","title":"Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.","url":"https://stock-news.laohu8.com/highlight/detail?id=1183532320","media":"老虎资讯综合","summary":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.","content":"<p>Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>The stock rebounded during the session, rising by more than 10% at one point, and was up 5.09% as of press time. It fell by more than 16% in early trading.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, Genshuixue released its unaudited financial reports for the fourth quarter and full year of fiscal year 2020. According to the report, Genshuixue's revenue reached 2.211 billion yuan in Q4 2020, a year-on-year increase of 136.5%, and the number of people paying for full-price courses increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report for fiscal year 2020 is the first quarter results of Genshuixue after merging all of its K12 business into \"Gaotu Classroom\". K12 online course revenue was RMB 1.975 billion, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. Cash revenue from K12 online courses was RMB 2.923 billion, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash revenue. The number of people paying for regular-price K12 online courses reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of the company's total number of people paying for regular-price courses.</p><p>Meanwhile, as of December 31, 2020, Genshuixue achieved revenue of RMB 7.125 billion in fiscal year 2020, a year-on-year increase of 236.9%, and the number of people paying for regular-price courses reached 5.871 million, a year-on-year increase of 168.4%. Among them, revenue from K-12 online courses reached 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people paying for regular-price K-12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of Genshuixue, said: \"Revenue hit a new high in the fourth quarter of 2020, reaching 2.21 billion yuan. Operating revenue in 2020 increased by 236.9% year-on-year to 7.12 billion yuan. Genshuixue achieved such growth and scale through efficient operations. In the fourth quarter alone, its net operating cash flow reached 636 million yuan, and its net operating cash flow continued to be positive throughout the year.\"</p><p>It is worth noting that on March 2 this year, Genshuixue issued an announcement stating that its independent investigation into multiple short-selling reports in 2020 has been basically completed. Based on the investigation results provided by the third-party professional advisors hired by the company's independent audit committee, no evidence of a material adverse impact on the company's historical financial statements was found.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-05 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>The stock rebounded during the session, rising by more than 10% at one point, and was up 5.09% as of press time. It fell by more than 16% in early trading.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, Genshuixue released its unaudited financial reports for the fourth quarter and full year of fiscal year 2020. According to the report, Genshuixue's revenue reached 2.211 billion yuan in Q4 2020, a year-on-year increase of 136.5%, and the number of people paying for full-price courses increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report for fiscal year 2020 is the first quarter results of Genshuixue after merging all of its K12 business into \"Gaotu Classroom\". K12 online course revenue was RMB 1.975 billion, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. Cash revenue from K12 online courses was RMB 2.923 billion, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash revenue. The number of people paying for regular-price K12 online courses reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of the company's total number of people paying for regular-price courses.</p><p>Meanwhile, as of December 31, 2020, Genshuixue achieved revenue of RMB 7.125 billion in fiscal year 2020, a year-on-year increase of 236.9%, and the number of people paying for regular-price courses reached 5.871 million, a year-on-year increase of 168.4%. Among them, revenue from K-12 online courses reached 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people paying for regular-price K-12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of Genshuixue, said: \"Revenue hit a new high in the fourth quarter of 2020, reaching 2.21 billion yuan. Operating revenue in 2020 increased by 236.9% year-on-year to 7.12 billion yuan. Genshuixue achieved such growth and scale through efficient operations. In the fourth quarter alone, its net operating cash flow reached 636 million yuan, and its net operating cash flow continued to be positive throughout the year.\"</p><p>It is worth noting that on March 2 this year, Genshuixue issued an announcement stating that its independent investigation into multiple short-selling reports in 2020 has been basically completed. Based on the investigation results provided by the third-party professional advisors hired by the company's independent audit committee, no evidence of a material adverse impact on the company's historical financial statements was found.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f49cfbbad938b58f9d764c4f5e672e9","relate_stocks":{"GSX":"Tradr 2X Long GS Daily ETF"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183532320","content_text":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.11亿元，同比增长136.5%，正价课付费人次同比增长107.6%达227.5万。2020财年Q4财报是跟谁学将K12业务全部合并至“高途课堂”后的首季成绩单，K12在线课程收入为19.75亿元，同比增长155.6%，占公司全部收入的89.33%，K12在线课程的现金收入为29.23亿元人民币，同比增长109.8%,，占公司全部现金收入的92.90%；K12在线课程正价课付费人次达到213.9万，同比增长112.8%，占公司全部正价课付费人次的94%。同时，截止到2020年12月31日，跟谁学2020财年全年实现收入71.25亿元，同比增长236.9%，正价课付费人次达587.1万，同比增长168.4%。其中，K12 在线课程收入为62.37亿元，同比增长265.5%，K12在线课程正价课付费人次达542.9万，同比增长177.3%。跟谁学创始人、董事长兼CEO陈向东表示：“2020年第四季度收入创造新高，达到22.1亿元。2020年营业收入同比增长了236.9%，为71.2亿元。跟谁学取得这样的增速和规模是通过高效率的运营达成的，仅第四季度单季经营净现金流就高达6.36亿元，全年经营净现金流也持续为正”。值得关注的是，今年3月2日，跟谁学发布公告称，针对2020年多份做空报告开展的独立调查已基本结束，根据公司独立审计委员会聘请的第三方专业顾问反馈的调查结果，没有发现对公司历史财务报表有重大不利影响的证据。","news_type":1,"symbols_score_info":{"GSX":0.9}},"isVote":1,"tweetType":1,"viewCount":3804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320086094,"gmtCreate":1614990789718,"gmtModify":1704777945082,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320086094","repostId":"1183532320","repostType":2,"repost":{"id":"1183532320","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614957526,"share":"https://ttm.financial/m/news/1183532320?lang=en_US&edition=fundamental","pubTime":"2021-03-05 23:18","market":"us","language":"zh","title":"Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.","url":"https://stock-news.laohu8.com/highlight/detail?id=1183532320","media":"老虎资讯综合","summary":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.","content":"<p>Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>The stock rebounded during the session, rising by more than 10% at one point, and was up 5.09% as of press time. It fell by more than 16% in early trading.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, Genshuixue released its unaudited financial reports for the fourth quarter and full year of fiscal year 2020. According to the report, Genshuixue's revenue reached 2.211 billion yuan in Q4 2020, a year-on-year increase of 136.5%, and the number of people paying for full-price courses increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report for fiscal year 2020 is the first quarter results of Genshuixue after merging all of its K12 business into \"Gaotu Classroom\". K12 online course revenue was RMB 1.975 billion, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. Cash revenue from K12 online courses was RMB 2.923 billion, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash revenue. The number of people paying for regular-price K12 online courses reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of the company's total number of people paying for regular-price courses.</p><p>Meanwhile, as of December 31, 2020, Genshuixue achieved revenue of RMB 7.125 billion in fiscal year 2020, a year-on-year increase of 236.9%, and the number of people paying for regular-price courses reached 5.871 million, a year-on-year increase of 168.4%. Among them, revenue from K-12 online courses reached 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people paying for regular-price K-12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of Genshuixue, said: \"Revenue hit a new high in the fourth quarter of 2020, reaching 2.21 billion yuan. Operating revenue in 2020 increased by 236.9% year-on-year to 7.12 billion yuan. Genshuixue achieved such growth and scale through efficient operations. In the fourth quarter alone, its net operating cash flow reached 636 million yuan, and its net operating cash flow continued to be positive throughout the year.\"</p><p>It is worth noting that on March 2 this year, Genshuixue issued an announcement stating that its independent investigation into multiple short-selling reports in 2020 has been basically completed. Based on the investigation results provided by the third-party professional advisors hired by the company's independent audit committee, no evidence of a material adverse impact on the company's historical financial statements was found.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-05 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>The stock rebounded during the session, rising by more than 10% at one point, and was up 5.09% as of press time. It fell by more than 16% in early trading.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, Genshuixue released its unaudited financial reports for the fourth quarter and full year of fiscal year 2020. According to the report, Genshuixue's revenue reached 2.211 billion yuan in Q4 2020, a year-on-year increase of 136.5%, and the number of people paying for full-price courses increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report for fiscal year 2020 is the first quarter results of Genshuixue after merging all of its K12 business into \"Gaotu Classroom\". K12 online course revenue was RMB 1.975 billion, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. Cash revenue from K12 online courses was RMB 2.923 billion, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash revenue. The number of people paying for regular-price K12 online courses reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of the company's total number of people paying for regular-price courses.</p><p>Meanwhile, as of December 31, 2020, Genshuixue achieved revenue of RMB 7.125 billion in fiscal year 2020, a year-on-year increase of 236.9%, and the number of people paying for regular-price courses reached 5.871 million, a year-on-year increase of 168.4%. Among them, revenue from K-12 online courses reached 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people paying for regular-price K-12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of Genshuixue, said: \"Revenue hit a new high in the fourth quarter of 2020, reaching 2.21 billion yuan. Operating revenue in 2020 increased by 236.9% year-on-year to 7.12 billion yuan. Genshuixue achieved such growth and scale through efficient operations. In the fourth quarter alone, its net operating cash flow reached 636 million yuan, and its net operating cash flow continued to be positive throughout the year.\"</p><p>It is worth noting that on March 2 this year, Genshuixue issued an announcement stating that its independent investigation into multiple short-selling reports in 2020 has been basically completed. Based on the investigation results provided by the third-party professional advisors hired by the company's independent audit committee, no evidence of a material adverse impact on the company's historical financial statements was found.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f49cfbbad938b58f9d764c4f5e672e9","relate_stocks":{"GSX":"Tradr 2X Long GS Daily ETF"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183532320","content_text":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.11亿元，同比增长136.5%，正价课付费人次同比增长107.6%达227.5万。2020财年Q4财报是跟谁学将K12业务全部合并至“高途课堂”后的首季成绩单，K12在线课程收入为19.75亿元，同比增长155.6%，占公司全部收入的89.33%，K12在线课程的现金收入为29.23亿元人民币，同比增长109.8%,，占公司全部现金收入的92.90%；K12在线课程正价课付费人次达到213.9万，同比增长112.8%，占公司全部正价课付费人次的94%。同时，截止到2020年12月31日，跟谁学2020财年全年实现收入71.25亿元，同比增长236.9%，正价课付费人次达587.1万，同比增长168.4%。其中，K12 在线课程收入为62.37亿元，同比增长265.5%，K12在线课程正价课付费人次达542.9万，同比增长177.3%。跟谁学创始人、董事长兼CEO陈向东表示：“2020年第四季度收入创造新高，达到22.1亿元。2020年营业收入同比增长了236.9%，为71.2亿元。跟谁学取得这样的增速和规模是通过高效率的运营达成的，仅第四季度单季经营净现金流就高达6.36亿元，全年经营净现金流也持续为正”。值得关注的是，今年3月2日，跟谁学发布公告称，针对2020年多份做空报告开展的独立调查已基本结束，根据公司独立审计委员会聘请的第三方专业顾问反馈的调查结果，没有发现对公司历史财务报表有重大不利影响的证据。","news_type":1,"symbols_score_info":{"GSX":0.9}},"isVote":1,"tweetType":1,"viewCount":2828,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":320086108,"gmtCreate":1614990798804,"gmtModify":1704777945890,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320086108","repostId":"1183532320","repostType":2,"repost":{"id":"1183532320","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614957526,"share":"https://ttm.financial/m/news/1183532320?lang=en_US&edition=fundamental","pubTime":"2021-03-05 23:18","market":"us","language":"zh","title":"Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.","url":"https://stock-news.laohu8.com/highlight/detail?id=1183532320","media":"老虎资讯综合","summary":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.","content":"<p>Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>The stock rebounded during the session, rising by more than 10% at one point, and was up 5.09% as of press time. It fell by more than 16% in early trading.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, Genshuixue released its unaudited financial reports for the fourth quarter and full year of fiscal year 2020. According to the report, Genshuixue's revenue reached 2.211 billion yuan in Q4 2020, a year-on-year increase of 136.5%, and the number of people paying for full-price courses increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report for fiscal year 2020 is the first quarter results of Genshuixue after merging all of its K12 business into \"Gaotu Classroom\". K12 online course revenue was RMB 1.975 billion, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. Cash revenue from K12 online courses was RMB 2.923 billion, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash revenue. The number of people paying for regular-price K12 online courses reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of the company's total number of people paying for regular-price courses.</p><p>Meanwhile, as of December 31, 2020, Genshuixue achieved revenue of RMB 7.125 billion in fiscal year 2020, a year-on-year increase of 236.9%, and the number of people paying for regular-price courses reached 5.871 million, a year-on-year increase of 168.4%. Among them, revenue from K-12 online courses reached 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people paying for regular-price K-12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of Genshuixue, said: \"Revenue hit a new high in the fourth quarter of 2020, reaching 2.21 billion yuan. Operating revenue in 2020 increased by 236.9% year-on-year to 7.12 billion yuan. Genshuixue achieved such growth and scale through efficient operations. In the fourth quarter alone, its net operating cash flow reached 636 million yuan, and its net operating cash flow continued to be positive throughout the year.\"</p><p>It is worth noting that on March 2 this year, Genshuixue issued an announcement stating that its independent investigation into multiple short-selling reports in 2020 has been basically completed. Based on the investigation results provided by the third-party professional advisors hired by the company's independent audit committee, no evidence of a material adverse impact on the company's historical financial statements was found.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-05 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>The stock rebounded during the session, rising by more than 10% at one point, and was up 5.09% as of press time. It fell by more than 16% in early trading.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, Genshuixue released its unaudited financial reports for the fourth quarter and full year of fiscal year 2020. According to the report, Genshuixue's revenue reached 2.211 billion yuan in Q4 2020, a year-on-year increase of 136.5%, and the number of people paying for full-price courses increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report for fiscal year 2020 is the first quarter results of Genshuixue after merging all of its K12 business into \"Gaotu Classroom\". K12 online course revenue was RMB 1.975 billion, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. Cash revenue from K12 online courses was RMB 2.923 billion, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash revenue. The number of people paying for regular-price K12 online courses reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of the company's total number of people paying for regular-price courses.</p><p>Meanwhile, as of December 31, 2020, Genshuixue achieved revenue of RMB 7.125 billion in fiscal year 2020, a year-on-year increase of 236.9%, and the number of people paying for regular-price courses reached 5.871 million, a year-on-year increase of 168.4%. Among them, revenue from K-12 online courses reached 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people paying for regular-price K-12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of Genshuixue, said: \"Revenue hit a new high in the fourth quarter of 2020, reaching 2.21 billion yuan. Operating revenue in 2020 increased by 236.9% year-on-year to 7.12 billion yuan. Genshuixue achieved such growth and scale through efficient operations. In the fourth quarter alone, its net operating cash flow reached 636 million yuan, and its net operating cash flow continued to be positive throughout the year.\"</p><p>It is worth noting that on March 2 this year, Genshuixue issued an announcement stating that its independent investigation into multiple short-selling reports in 2020 has been basically completed. Based on the investigation results provided by the third-party professional advisors hired by the company's independent audit committee, no evidence of a material adverse impact on the company's historical financial statements was found.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f49cfbbad938b58f9d764c4f5e672e9","relate_stocks":{"GSX":"Tradr 2X Long GS Daily ETF"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183532320","content_text":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.11亿元，同比增长136.5%，正价课付费人次同比增长107.6%达227.5万。2020财年Q4财报是跟谁学将K12业务全部合并至“高途课堂”后的首季成绩单，K12在线课程收入为19.75亿元，同比增长155.6%，占公司全部收入的89.33%，K12在线课程的现金收入为29.23亿元人民币，同比增长109.8%,，占公司全部现金收入的92.90%；K12在线课程正价课付费人次达到213.9万，同比增长112.8%，占公司全部正价课付费人次的94%。同时，截止到2020年12月31日，跟谁学2020财年全年实现收入71.25亿元，同比增长236.9%，正价课付费人次达587.1万，同比增长168.4%。其中，K12 在线课程收入为62.37亿元，同比增长265.5%，K12在线课程正价课付费人次达542.9万，同比增长177.3%。跟谁学创始人、董事长兼CEO陈向东表示：“2020年第四季度收入创造新高，达到22.1亿元。2020年营业收入同比增长了236.9%，为71.2亿元。跟谁学取得这样的增速和规模是通过高效率的运营达成的，仅第四季度单季经营净现金流就高达6.36亿元，全年经营净现金流也持续为正”。值得关注的是，今年3月2日，跟谁学发布公告称，针对2020年多份做空报告开展的独立调查已基本结束，根据公司独立审计委员会聘请的第三方专业顾问反馈的调查结果，没有发现对公司历史财务报表有重大不利影响的证据。","news_type":1,"symbols_score_info":{"GSX":0.9}},"isVote":1,"tweetType":1,"viewCount":3804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320086094,"gmtCreate":1614990789718,"gmtModify":1704777945082,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320086094","repostId":"1183532320","repostType":2,"repost":{"id":"1183532320","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614957526,"share":"https://ttm.financial/m/news/1183532320?lang=en_US&edition=fundamental","pubTime":"2021-03-05 23:18","market":"us","language":"zh","title":"Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.","url":"https://stock-news.laohu8.com/highlight/detail?id=1183532320","media":"老虎资讯综合","summary":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.","content":"<p>Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>The stock rebounded during the session, rising by more than 10% at one point, and was up 5.09% as of press time. It fell by more than 16% in early trading.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, Genshuixue released its unaudited financial reports for the fourth quarter and full year of fiscal year 2020. According to the report, Genshuixue's revenue reached 2.211 billion yuan in Q4 2020, a year-on-year increase of 136.5%, and the number of people paying for full-price courses increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report for fiscal year 2020 is the first quarter results of Genshuixue after merging all of its K12 business into \"Gaotu Classroom\". K12 online course revenue was RMB 1.975 billion, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. Cash revenue from K12 online courses was RMB 2.923 billion, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash revenue. The number of people paying for regular-price K12 online courses reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of the company's total number of people paying for regular-price courses.</p><p>Meanwhile, as of December 31, 2020, Genshuixue achieved revenue of RMB 7.125 billion in fiscal year 2020, a year-on-year increase of 236.9%, and the number of people paying for regular-price courses reached 5.871 million, a year-on-year increase of 168.4%. Among them, revenue from K-12 online courses reached 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people paying for regular-price K-12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of Genshuixue, said: \"Revenue hit a new high in the fourth quarter of 2020, reaching 2.21 billion yuan. Operating revenue in 2020 increased by 236.9% year-on-year to 7.12 billion yuan. Genshuixue achieved such growth and scale through efficient operations. In the fourth quarter alone, its net operating cash flow reached 636 million yuan, and its net operating cash flow continued to be positive throughout the year.\"</p><p>It is worth noting that on March 2 this year, Genshuixue issued an announcement stating that its independent investigation into multiple short-selling reports in 2020 has been basically completed. Based on the investigation results provided by the third-party professional advisors hired by the company's independent audit committee, no evidence of a material adverse impact on the company's historical financial statements was found.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenshuixue open low rose sharply, reversing a 16% decline and gaining over 10% intraday.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-05 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>The stock rebounded during the session, rising by more than 10% at one point, and was up 5.09% as of press time. It fell by more than 16% in early trading.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, Genshuixue released its unaudited financial reports for the fourth quarter and full year of fiscal year 2020. According to the report, Genshuixue's revenue reached 2.211 billion yuan in Q4 2020, a year-on-year increase of 136.5%, and the number of people paying for full-price courses increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report for fiscal year 2020 is the first quarter results of Genshuixue after merging all of its K12 business into \"Gaotu Classroom\". K12 online course revenue was RMB 1.975 billion, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. Cash revenue from K12 online courses was RMB 2.923 billion, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash revenue. The number of people paying for regular-price K12 online courses reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of the company's total number of people paying for regular-price courses.</p><p>Meanwhile, as of December 31, 2020, Genshuixue achieved revenue of RMB 7.125 billion in fiscal year 2020, a year-on-year increase of 236.9%, and the number of people paying for regular-price courses reached 5.871 million, a year-on-year increase of 168.4%. Among them, revenue from K-12 online courses reached 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people paying for regular-price K-12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of Genshuixue, said: \"Revenue hit a new high in the fourth quarter of 2020, reaching 2.21 billion yuan. Operating revenue in 2020 increased by 236.9% year-on-year to 7.12 billion yuan. Genshuixue achieved such growth and scale through efficient operations. In the fourth quarter alone, its net operating cash flow reached 636 million yuan, and its net operating cash flow continued to be positive throughout the year.\"</p><p>It is worth noting that on March 2 this year, Genshuixue issued an announcement stating that its independent investigation into multiple short-selling reports in 2020 has been basically completed. Based on the investigation results provided by the third-party professional advisors hired by the company's independent audit committee, no evidence of a material adverse impact on the company's historical financial statements was found.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f49cfbbad938b58f9d764c4f5e672e9","relate_stocks":{"GSX":"Tradr 2X Long GS Daily ETF"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183532320","content_text":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.11亿元，同比增长136.5%，正价课付费人次同比增长107.6%达227.5万。2020财年Q4财报是跟谁学将K12业务全部合并至“高途课堂”后的首季成绩单，K12在线课程收入为19.75亿元，同比增长155.6%，占公司全部收入的89.33%，K12在线课程的现金收入为29.23亿元人民币，同比增长109.8%,，占公司全部现金收入的92.90%；K12在线课程正价课付费人次达到213.9万，同比增长112.8%，占公司全部正价课付费人次的94%。同时，截止到2020年12月31日，跟谁学2020财年全年实现收入71.25亿元，同比增长236.9%，正价课付费人次达587.1万，同比增长168.4%。其中，K12 在线课程收入为62.37亿元，同比增长265.5%，K12在线课程正价课付费人次达542.9万，同比增长177.3%。跟谁学创始人、董事长兼CEO陈向东表示：“2020年第四季度收入创造新高，达到22.1亿元。2020年营业收入同比增长了236.9%，为71.2亿元。跟谁学取得这样的增速和规模是通过高效率的运营达成的，仅第四季度单季经营净现金流就高达6.36亿元，全年经营净现金流也持续为正”。值得关注的是，今年3月2日，跟谁学发布公告称，针对2020年多份做空报告开展的独立调查已基本结束，根据公司独立审计委员会聘请的第三方专业顾问反馈的调查结果，没有发现对公司历史财务报表有重大不利影响的证据。","news_type":1,"symbols_score_info":{"GSX":0.9}},"isVote":1,"tweetType":1,"viewCount":2828,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811218252,"gmtCreate":1630326149476,"gmtModify":1676530269198,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811218252","repostId":"2163012390","repostType":2,"repost":{"id":"2163012390","kind":"news","pubTimestamp":1630308776,"share":"https://ttm.financial/m/news/2163012390?lang=en_US&edition=fundamental","pubTime":"2021-08-30 15:32","market":"hk","language":"zh","title":"UBS: Gives WuXi Biologics (02269) a \"Buy\" rating with a target price of HK$142","url":"https://stock-news.laohu8.com/highlight/detail?id=2163012390","media":"智通财经","summary":"智通财经APP获悉，瑞银发布研究报告称，予药明生物“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。","content":"<p><html><body>According to Zhitong Finance APP,<a href=\"https://laohu8.com/S/UBS\">UBS</a>A research report was released stating that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) has a \"Buy\" rating with a target price of HK$142, raising its 2021-23 earnings per share forecast by 26% to 38% to reflect stronger-than-expected pandemic and CMO-related projects, and raising its 2020-24 revenue forecast by 11% to reflect stronger-than-expected growth in COVID-19 projects and growth in pharmaceutical manufacturing outsourcing (CMO).</p><p>The report stated that, according to management, there will be at least four to five non-COVID-19-related CMOs by the end of 2022, which is expected to drive the company's long-term profit growth. Management will maintain its 2021 guidance, expecting revenue and net profit to increase by 65% year-on-year. The bank believes that if growth is not affected by supply shortages, the company is expected to outperform the guidance.</p><p>The bank stated that, according to management, there is currently no evidence that the U.S. government will restrict U.S. companies from using CDMO companies based in China. Meanwhile, 20% of WuXi AppTec's customers have considered using the company's production capacity in Europe and the United States to mitigate risks. Considering the nature of the company's CDMO services, if drugs are produced in Europe and the United States and shipped there, they will not be considered exported from China to the United States, which is believed to reduce the risk of drug supply instability.</p><p></body></html></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS: Gives WuXi Biologics (02269) a \"Buy\" rating with a target price of HK$142</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS: Gives WuXi Biologics (02269) a \"Buy\" rating with a target price of HK$142\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-30 15:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>According to Zhitong Finance APP,<a href=\"https://laohu8.com/S/UBS\">UBS</a>A research report was released stating that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) has a \"Buy\" rating with a target price of HK$142, raising its 2021-23 earnings per share forecast by 26% to 38% to reflect stronger-than-expected pandemic and CMO-related projects, and raising its 2020-24 revenue forecast by 11% to reflect stronger-than-expected growth in COVID-19 projects and growth in pharmaceutical manufacturing outsourcing (CMO).</p><p>The report stated that, according to management, there will be at least four to five non-COVID-19-related CMOs by the end of 2022, which is expected to drive the company's long-term profit growth. Management will maintain its 2021 guidance, expecting revenue and net profit to increase by 65% year-on-year. The bank believes that if growth is not affected by supply shortages, the company is expected to outperform the guidance.</p><p>The bank stated that, according to management, there is currently no evidence that the U.S. government will restrict U.S. companies from using CDMO companies based in China. Meanwhile, 20% of WuXi AppTec's customers have considered using the company's production capacity in Europe and the United States to mitigate risks. Considering the nature of the company's CDMO services, if drugs are produced in Europe and the United States and shipped there, they will not be considered exported from China to the United States, which is believed to reduce the risk of drug supply instability.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/549312.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"02269":"药明生物"},"source_url":"http://www.zhitongcaijing.com/content/detail/549312.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163012390","content_text":"智通财经APP获悉，瑞银发布研究报告称，予药明生物(02269)“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包(CMO)增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。该行表示，据管理层指，现时未有证据美国政府将限制美国企业使用以中国为基地的CDMO企业，同时有20%药明的客户已考虑使用公司于欧美的产能以减低风险，考虑公司CDMO服务性质，假如药物于欧美生产并运往当地，将不被视作由中国出口至美国，相信可减低药物供应不稳的风险。","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":3110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835151166,"gmtCreate":1629696705355,"gmtModify":1676530102959,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835151166","repostId":"2161725272","repostType":2,"repost":{"id":"2161725272","kind":"news","pubTimestamp":1629684392,"share":"https://ttm.financial/m/news/2161725272?lang=en_US&edition=fundamental","pubTime":"2021-08-23 10:06","market":"us","language":"zh","title":"[Stocks in Focus] WuXi Biologics (02269.HK) rose 3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2161725272","media":"金融界网站","summary":"【财华社讯】药明生物(02269.HK)截至10:06上涨3.13%，现报108.6港元，涨3.3港元。成交375万股，涉资3.967亿元。（出处：FinetAI）","content":"<p><html><body><div>[Caihua News Agency]<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269.HK) rose 3.13% as of 10:06 and is currently trading at HK$108.6, up HK$3.3. 3.75 million shares were traded, involving 396.7 million yuan. (Source: FinetAI)</p><p><div></div></div></body></html></p>","source":"jinrongjie_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[Stocks in Focus] WuXi Biologics (02269.HK) rose 3.13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[Stocks in Focus] WuXi Biologics (02269.HK) rose 3.13%\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">金融界网站</strong><span class=\"h-time small\">2021-08-23 10:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div>[Caihua News Agency]<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269.HK) rose 3.13% as of 10:06 and is currently trading at HK$108.6, up HK$3.3. 3.75 million shares were traded, involving 396.7 million yuan. (Source: FinetAI)</p><p><div></div></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://hk.jrj.com.cn/2021/08/23100633301119.shtml\">金融界网站</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","relate_stocks":{"02269":"药明生物"},"source_url":"http://hk.jrj.com.cn/2021/08/23100633301119.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161725272","content_text":"【财华社讯】药明生物(02269.HK)截至10:06上涨3.13%，现报108.6港元，涨3.3港元。成交375万股，涉资3.967亿元。（出处：FinetAI）","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":3913,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811103906,"gmtCreate":1630293590105,"gmtModify":1676530259718,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811103906","repostId":"2163702540","repostType":2,"repost":{"id":"2163702540","kind":"news","pubTimestamp":1630285168,"share":"https://ttm.financial/m/news/2163702540?lang=en_US&edition=fundamental","pubTime":"2021-08-30 08:59","market":"us","language":"zh","title":"Driven by dual business engines and a sound strategic layout, Beijing Energy Clean Energy (0579.HK) saw steady improvement in its interim results.","url":"https://stock-news.laohu8.com/highlight/detail?id=2163702540","media":"格隆汇","summary":"总结来说，整个2021年上半年，京能清洁能源凭借其自身的软硬实力，充分发挥多元化的竞争优势，使得各个业务板块实现稳健增长。","content":"<p><html><body><span>On August 26, Hong Kong stocks<a href=\"https://laohu8.com/S/00579\">Jingneng Clean Energy</a>(0579.HK) announced its 2021 interim results: it achieved operating revenue of RMB 9.34 billion, a year-on-year increase of 12.81%; Profit before tax was RMB1,884 million, representing a year-on-year increase of 13.90%; Profit attributable to ordinary shareholders of the company was RMB 1.488 billion, representing a year-on-year increase of 14.90%; Basic and diluted earnings per share were RMB18.05 cents.</span></p><p>This is an excellent report card. In the fiercely competitive market environment, Beijing Energy Clean Energy achieved double-digit year-on-year growth in both revenue and net profit in the first half of this year. It can be said that it has made progress while maintaining stability and has strong momentum to move forward.</p><p><b><font color=\"#ff0000\">1. Steady business growth and further consolidation of industry position</font></b></p><p>The semi-annual performance report released by Beijing Energy Clean Energy shows that while its operating performance has grown steadily, it has also performed well in multiple business dimensions and has been continuously optimized.</p><p><b>Installed capacity has steadily increased.</b>As of June 30, 2021, the company's total installed capacity was 11.215 million kilowatts, a year-on-year increase of 14%. Among them, the wind power business segment added 349,000 kilowatts of installed capacity, all of which came from self-built projects.</p><p><b>Electricity generation showed a significant increase.</b>As of June 30, 2021, the company's total controlled power generation reached 16.179 billion kilowatt-hours, representing a year-on-year increase of 17.73%.</p><p>Among them, the power generation of the gas power generation and heating business segment increased by 8.08% year-on-year;<b>The wind power generation business segment's power generation increased by 44.43% year-on-year; The photovoltaic power generation business segment's power generation increased by 37.87% year-on-year, significantly higher than the national industry level during the same period.</b></p><p><b>In summary,</b>Throughout the first half of 2021, Beijing Energy Clean Energy leveraged its own soft and hard strengths to fully utilize its diversified competitive advantages, enabling its various business segments to achieve steady growth.</p><p>In particular, the photovoltaic sector exceeded the national average during the same period, fully catering to the development concepts of \"30, 60\" and \"carbon peaking and carbon neutrality\", and further consolidating the company's leading position in the industry as a local new energy state-owned enterprise.</p><p><b><font color=\"#ff0000\">2. Driven by both independent development and project mergers and acquisitions, business synergy is highlighted.</font></b></p><p>When judging a company's growth, there are often two points worth paying attention to. First, the growth of endogenous driving forces, that is, relying on the company's own accumulation and accumulating strength before making a breakthrough. Secondly, external mergers and acquisitions integrate markets, resources, and technology through mergers and acquisitions, achieving rapid development under efficient corporate internal control capabilities.</p><p><b>In terms of endogenous growth, we will continue to accelerate the pace of independent project development and construction.</b>According to the interim report, as of the first half of 2021, the company had independently developed 18 wind power and photovoltaic projects that had obtained construction quotas, with an installed capacity of 1.754 million kilowatts.</p><p>Among them, the \"Beijing-Zhangjiakou Olympic Wind Power Project\" undertaken by the company utilizes the abundant wind power resources of the Zhangjiakou area and takes advantage of the joint bid by Beijing and Hebei Province to host the 2022 Olympic and Paralympic Winter Games. It transmits wind power from the Zhangjiakou area to the Beijing power grid for winter heating. At the same time, it contributes the strength of a state-owned enterprise in the capital to the 2022 Beijing Olympic and Paralympic Winter Games Committee, which achieved green electricity coverage for all venues for the first time in Olympic history.</p><p>Moreover, the construction of this project has enabled the development and utilization of the local abundant wind energy resources, playing a significant role in promoting the development of the regional economy. At the same time, it has greatly optimized Beijing's energy structure, which is more conducive to the implementation and effectiveness of the central government's strategic plan for the coordinated development of the \"Beijing-Tianjin-Hebei integration\".</p><p>It is understood that the total installed capacity of the project is 1.2 million kilowatts. Among them, Beijing Energy Clean Energy has a self-built capacity of 775,000 kilowatts. To date, it has completed the transfer of the Dongxu Shangyi 200,000 kilowatt wind power project and the Guoxin Haojiaying 100,000 kilowatt wind power project. Beijing Energy Clean Energy manages an installed capacity of 1.075 million kilowatts, with a total investment of approximately 9 billion yuan.</p><p><b>In terms of external expansion, we will vigorously expand our business through project mergers and acquisitions. As of the first half of 2021,</b>A total of 13 wind power and photovoltaic projects are currently undergoing mergers and acquisitions, with an installed capacity of 1.486 million kilowatts. In July of this year, the company entered into an equity transfer agreement with Ningxia Jiaze for Kaiyang and Boyang, acquiring the 297.5MW wind power and photovoltaic project in Hongsipu, Ningxia, and the 99MW wind power project in Tongxin, Ningxia, contributing to the growth of Beijing Energy Clean Energy's installed capacity in the second half of the year.</p><p>It is worth mentioning that,<b>This acquisition will facilitate the intensive management of Beijing Energy Clean Energy's Northwest Branch and will create good synergies with the company's existing assets. It can not only achieve the goals of complementary advantages, learning from each other's strengths and weaknesses, reducing costs and increasing efficiency, and enabling business synergy, but also enable the company to form a nationwide and comprehensive strategic layout.</b></p><p><b>In fact, mergers and acquisitions are an inevitable path to increased concentration in the new energy industry and a manifestation of internal reshuffling within the industry.</b>With the increasing cost of self-built projects across the industry, seeking to acquire projects through mergers and acquisitions, or even acquiring other industries to fill gaps in business layout and expand scale, has become one of the new business models for new energy companies.</p><p>For new energy companies, shifting from pure competition to cooperation not only allows them to leverage each other's strengths, but also mitigates investment risks to a certain extent and maximizes profits. At the same time, we can leverage the strengths of each company to make the company the best it can be.</p><p>Therefore, in the long run, with changes in the market environment, the future development model of new energy companies will be not only to hone their internal capabilities and enhance their core strength, but also to acquire more resources through mergers and acquisitions, restructuring and other means, and to try in multiple fields. \"Dual-wheel drive\" or even \"four-wheel drive\" will be the future growth path of new energy companies. Beijing Energy Clean Energy has officially embarked on this high-speed road of \"becoming stronger and bigger\".</p><p></body></html></p>","source":"stock_gelonghui","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Driven by dual business engines and a sound strategic layout, Beijing Energy Clean Energy (0579.HK) saw steady improvement in its interim results.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDriven by dual business engines and a sound strategic layout, Beijing Energy Clean Energy (0579.HK) saw steady improvement in its interim results.\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">格隆汇</strong><span class=\"h-time small\">2021-08-30 08:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><span>On August 26, Hong Kong stocks<a href=\"https://laohu8.com/S/00579\">Jingneng Clean Energy</a>(0579.HK) announced its 2021 interim results: it achieved operating revenue of RMB 9.34 billion, a year-on-year increase of 12.81%; Profit before tax was RMB1,884 million, representing a year-on-year increase of 13.90%; Profit attributable to ordinary shareholders of the company was RMB 1.488 billion, representing a year-on-year increase of 14.90%; Basic and diluted earnings per share were RMB18.05 cents.</span></p><p>This is an excellent report card. In the fiercely competitive market environment, Beijing Energy Clean Energy achieved double-digit year-on-year growth in both revenue and net profit in the first half of this year. It can be said that it has made progress while maintaining stability and has strong momentum to move forward.</p><p><b><font color=\"#ff0000\">1. Steady business growth and further consolidation of industry position</font></b></p><p>The semi-annual performance report released by Beijing Energy Clean Energy shows that while its operating performance has grown steadily, it has also performed well in multiple business dimensions and has been continuously optimized.</p><p><b>Installed capacity has steadily increased.</b>As of June 30, 2021, the company's total installed capacity was 11.215 million kilowatts, a year-on-year increase of 14%. Among them, the wind power business segment added 349,000 kilowatts of installed capacity, all of which came from self-built projects.</p><p><b>Electricity generation showed a significant increase.</b>As of June 30, 2021, the company's total controlled power generation reached 16.179 billion kilowatt-hours, representing a year-on-year increase of 17.73%.</p><p>Among them, the power generation of the gas power generation and heating business segment increased by 8.08% year-on-year;<b>The wind power generation business segment's power generation increased by 44.43% year-on-year; The photovoltaic power generation business segment's power generation increased by 37.87% year-on-year, significantly higher than the national industry level during the same period.</b></p><p><b>In summary,</b>Throughout the first half of 2021, Beijing Energy Clean Energy leveraged its own soft and hard strengths to fully utilize its diversified competitive advantages, enabling its various business segments to achieve steady growth.</p><p>In particular, the photovoltaic sector exceeded the national average during the same period, fully catering to the development concepts of \"30, 60\" and \"carbon peaking and carbon neutrality\", and further consolidating the company's leading position in the industry as a local new energy state-owned enterprise.</p><p><b><font color=\"#ff0000\">2. Driven by both independent development and project mergers and acquisitions, business synergy is highlighted.</font></b></p><p>When judging a company's growth, there are often two points worth paying attention to. First, the growth of endogenous driving forces, that is, relying on the company's own accumulation and accumulating strength before making a breakthrough. Secondly, external mergers and acquisitions integrate markets, resources, and technology through mergers and acquisitions, achieving rapid development under efficient corporate internal control capabilities.</p><p><b>In terms of endogenous growth, we will continue to accelerate the pace of independent project development and construction.</b>According to the interim report, as of the first half of 2021, the company had independently developed 18 wind power and photovoltaic projects that had obtained construction quotas, with an installed capacity of 1.754 million kilowatts.</p><p>Among them, the \"Beijing-Zhangjiakou Olympic Wind Power Project\" undertaken by the company utilizes the abundant wind power resources of the Zhangjiakou area and takes advantage of the joint bid by Beijing and Hebei Province to host the 2022 Olympic and Paralympic Winter Games. It transmits wind power from the Zhangjiakou area to the Beijing power grid for winter heating. At the same time, it contributes the strength of a state-owned enterprise in the capital to the 2022 Beijing Olympic and Paralympic Winter Games Committee, which achieved green electricity coverage for all venues for the first time in Olympic history.</p><p>Moreover, the construction of this project has enabled the development and utilization of the local abundant wind energy resources, playing a significant role in promoting the development of the regional economy. At the same time, it has greatly optimized Beijing's energy structure, which is more conducive to the implementation and effectiveness of the central government's strategic plan for the coordinated development of the \"Beijing-Tianjin-Hebei integration\".</p><p>It is understood that the total installed capacity of the project is 1.2 million kilowatts. Among them, Beijing Energy Clean Energy has a self-built capacity of 775,000 kilowatts. To date, it has completed the transfer of the Dongxu Shangyi 200,000 kilowatt wind power project and the Guoxin Haojiaying 100,000 kilowatt wind power project. Beijing Energy Clean Energy manages an installed capacity of 1.075 million kilowatts, with a total investment of approximately 9 billion yuan.</p><p><b>In terms of external expansion, we will vigorously expand our business through project mergers and acquisitions. As of the first half of 2021,</b>A total of 13 wind power and photovoltaic projects are currently undergoing mergers and acquisitions, with an installed capacity of 1.486 million kilowatts. In July of this year, the company entered into an equity transfer agreement with Ningxia Jiaze for Kaiyang and Boyang, acquiring the 297.5MW wind power and photovoltaic project in Hongsipu, Ningxia, and the 99MW wind power project in Tongxin, Ningxia, contributing to the growth of Beijing Energy Clean Energy's installed capacity in the second half of the year.</p><p>It is worth mentioning that,<b>This acquisition will facilitate the intensive management of Beijing Energy Clean Energy's Northwest Branch and will create good synergies with the company's existing assets. It can not only achieve the goals of complementary advantages, learning from each other's strengths and weaknesses, reducing costs and increasing efficiency, and enabling business synergy, but also enable the company to form a nationwide and comprehensive strategic layout.</b></p><p><b>In fact, mergers and acquisitions are an inevitable path to increased concentration in the new energy industry and a manifestation of internal reshuffling within the industry.</b>With the increasing cost of self-built projects across the industry, seeking to acquire projects through mergers and acquisitions, or even acquiring other industries to fill gaps in business layout and expand scale, has become one of the new business models for new energy companies.</p><p>For new energy companies, shifting from pure competition to cooperation not only allows them to leverage each other's strengths, but also mitigates investment risks to a certain extent and maximizes profits. At the same time, we can leverage the strengths of each company to make the company the best it can be.</p><p>Therefore, in the long run, with changes in the market environment, the future development model of new energy companies will be not only to hone their internal capabilities and enhance their core strength, but also to acquire more resources through mergers and acquisitions, restructuring and other means, and to try in multiple fields. \"Dual-wheel drive\" or even \"four-wheel drive\" will be the future growth path of new energy companies. Beijing Energy Clean Energy has officially embarked on this high-speed road of \"becoming stronger and bigger\".</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://www.gelonghui.com/news/detail.html?id=608034\">格隆汇</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f01e4b782ba393cb7794f7764a5d7d90","relate_stocks":{"00579":"京能清洁能源"},"source_url":"https://www.gelonghui.com/news/detail.html?id=608034","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163702540","content_text":"8月26日，港股京能清洁能源(0579.HK)公布2021中期业绩报告：实现营业收入人民币93.40亿元，同比增长12.81%；除税前溢利为人民币18.84亿元，同比增长13.90%；公司普通股股东应占溢利为人民币14.88亿元，同比增长14.90%；每股基本及摊薄盈利人民币18.05分。这是一份优异的成绩单，在竞争激烈的市场环境下，今年上半年，京能清洁能源的营收、净利润同比增速双双取得两位数增长，可以说“稳”中有进，前进动力十足。1、业务稳健增长，行业地位进一步巩固通过京能清洁能源发布的半年度业绩报告，可以发现在经营业绩稳健增长的同时，在多个业务维度均有不俗表现，并且得到持续优化。装机容量稳步提高，截至2021年6月30日，公司控股总装机容量为1,121.5万千瓦，同比增长14%，其中，风力发电业务板块新增装机容量34.9万千瓦，全部来自于自建项目。发电量呈现较大幅度的增长。截至2021年6月30日，公司控股总发电量为161.79亿千瓦时，同比增长17.73%。其中燃气发电及供热业务板块发电量同比增长8.08%；风力发电业务板块发电量同比增长44.43%；光伏发电业务板块发电量同比增长37.87%，明显高于全国行业同期水平。总结来说，整个2021年上半年，京能清洁能源凭借其自身的软硬实力，充分发挥多元化的竞争优势，使得各个业务板块实现稳健增长。尤其是光伏板块更是超过全国同期的水平，充分迎合“30,60”、“碳达峰、碳中和”的发展理念，进一步巩固了公司作为地方新能源国企的行业领先地位。2、自主开发与项目并购双轮驱动，业务协同效应凸显评判一家企业的增长，往往有两个看点值得关注，其一，内生动力的增长，即依靠企业自身积累，厚积薄发；其二，外延式并购，通过收并购，实现市场、资源、技术的整合，在高效的企业内控能力之下，实现高速发展。 在内生动力增长方面，不断加快自主项目开发、建设的步伐。根据中报数据显示，截至2021年上半年，公司自主开发取得建设指标的风电、光伏项目18个，装机容量175.4万千瓦。 其中，公司承建的“京张奥运风电项目”，利用张家口地区丰富的风电资源，以北京市和河北省联合申办冬奥委会为契机，将张家口地区风电输送至北京电网以冬季供热方式进行消纳，同时为2022年北京冬奥委会在奥运史上首次实现全部场馆绿色电力覆盖的创举贡献首都国企的一份力量。不仅如此，该项目的建设让当地丰富的风能资源得到了开发与利用，对发展地区经济起到巨大的推动作用。同时极大地优化了北京能源结构，更有利于中央“京津冀一体化”协同发展的战略部署落地、产生实效。据了解，该项目总装机容量120万千瓦。其中京能清洁能源自建容量77.5万千瓦，截至目前，已经完成了东旭尚义20万千瓦风电项目、国新郝家营10万千瓦风电项目股转。京能清洁能源管理装机容量达107.5万千瓦，项目总投资约90亿元。在外延式扩张上，通过项目并购的方式大力拓展业务。截至2021年上半年，正在开展并购工作的风电、光伏项目共计13个，装机容量148.6万千瓦。今年7月份，公司与宁夏嘉泽订立了恺阳及博阳股权转让协议，收购了宁夏红寺堡297.5MW风电、光伏项目及宁夏同心99MW风电项目，为京能清洁能源下半年的装机容量增长贡献了一份力量。值得一提的是，此次收购有利于京能清洁能源西北分公司的集约化管理，将与公司既有资产形成较好的协同效应。不仅可以达到优势互补，取长补短，降本增效，业务相互协同的目的，还可以让公司形成全国化、全方位的战略布局。事实上，收购并购是新能源行业集中度增强的必经之路，也是行业内部洗牌的一种表现。随着整体行业自建项目成本的增加，寻求通过并购形式收购股权获得项目，甚至收购其他行业填补业态布局短板、扩大规模已成为新能源企业新的经营模式之一。对新能源企业而言，由之前的纯竞争转为合作，不仅可以相互借力，一定程度上规避投资风险，实现利益最大化。同时，还可以发挥各家所长，把企业做到最好。因此，长期来看，随着市场环境的变化，新能源企业未来的发展模式，除了苦练内功，增强自身的硬核实力之外，以并购、重组等形式来获取更多资源，多领域的尝试，“双轮驱动”以至“四轮驱动”将是新能源的企业未来成长之路，京能清洁能源已正式踏上了这条“做强、做大”的高速之路。","news_type":1,"symbols_score_info":{"00579":1}},"isVote":1,"tweetType":1,"viewCount":3946,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811109949,"gmtCreate":1630293486281,"gmtModify":1676530259693,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811109949","repostId":"1167910924","repostType":2,"repost":{"id":"1167910924","kind":"news","pubTimestamp":1630284735,"share":"https://ttm.financial/m/news/1167910924?lang=en_US&edition=fundamental","pubTime":"2021-08-30 08:52","market":"hk","language":"zh","title":"Why did Haidilao target Zhang Yong's wife and founder?","url":"https://stock-news.laohu8.com/highlight/detail?id=1167910924","media":"联商网资讯","summary":"这些年，作为火锅界的大哥，海底捞的日子过得并不太顺利。\n6月15日，在股东大会上，有人问，海底捞能否持续增长？董事长张勇耿直地回答：“大家神话海底捞了，我本人非常反感。我作为海底捞最大的股东，我是不抱","content":"<p>Over the years, as a leader in the hot pot industry,<a href=\"https://laohu8.com/S/06862\">Haidilao</a>Life wasn't going very smoothly.</p><p>On June 15, at the shareholders' meeting, someone asked whether Haidilao could continue to grow. Chairman Zhang Yong answered frankly: \"Everyone has mythologized Haidilao, which I personally find very offensive. As Haidilao's largest shareholder, I have no hope.\"</p><p>Zhang Yong said, \"I often say that if you want to know what it means to not live up to its name, just look at Haidilao. We face the same difficulties that all catering companies face; we still haven't solved the problems that all catering companies can't solve.\"</p><p>What Zhang Yong said was the truth and reliability. Of course, it cannot be ruled out that it was paving the way for Haidilao's declining performance and serving as a precaution. Investors should be mentally prepared.</p><p><b>01</b></p><p><b>Personnel changes</b></p><p><b>The team introduced fresh blood</b></p><p>On August 24, Haidilao announced that, effective immediately, Shu Ping had resigned as a non-executive director and member of the audit committee, and Shi Yonghong had resigned as an executive director. Both are the founders of Haidilao, and Shu Ping is the wife of Chairman Zhang Yong.</p><p>Haidilao stated that Shu Ping's resignation was due to an internal organizational restructuring, while Shi Yonghong's was to devote more time and energy to other businesses. Shu Ping became a director of the company in 2015 and was re-designated as a non-executive director in 2018, primarily responsible for overseeing the group's management and strategic development.</p><p>Shi Yonghong is the second-in-command of Haidilao and one of its founders. He became a director of the company in 2015 and was re-designated as an executive director in 2018, primarily responsible for participating in and overseeing the group's management and strategic development. In addition to working for the group, Shi Yonghong is also a hot pot ingredient supplier under Haidilao.<a href=\"https://laohu8.com/S/01579\">Yihai International</a>He is the executive director and chairman of Haidilao and holds director positions in several member companies of Haidilao.</p><p>The announcement also stated that Yang Lijuan has been appointed as the company's deputy CEO, and Cai Xinmin has been appointed as a member of the company's audit committee. Seven new executive directors, Yang Lijuan, Li Peng, Yang Hua, Liu Linyi, Li Yu, Song Qing, and Yang Li, and two new independent non-executive directors, Ma Weihua and Wu Xiaoguang, were added.</p><p>Prior to this appointment, Yang Lijuan was Haidilao's Chief Operating Officer, primarily responsible for overseeing the group's operations. Following this appointment, Yang Lijuan will be responsible for assisting the CEO in managing the group's overall operations.</p><p>In the first half of this year, Haidilao changed its organizational structure, changing the regional coordination coaching model to a large and community management model. Existing stores will be divided into five regions by geographical area, with regional managers coordinating store expansion, engineering, product selection, pricing, and other work within the region. Each district is divided into several communities, and community managers conduct on-site inspections, assessments, and guidance of stores within the area.</p><p>Haidilao stated that it hopes to accurately identify the problems existing in each store through organizational restructuring and provide continuous supervision and guidance.</p><p>According to reports, the new executive directors are all around 40 years old, most of whom were trained by Haidilao from the grassroots level and have rich front-line work experience. Yang Lijuan started her business with Zhang Yong in 1997 and was the first waitress Zhang Yong poached. After Haidilao went public, Yang Lijuan became the \"top waitress,\" holding 179 million shares of the company and a net worth of over 5 billion yuan.</p><p>In 1994, Shi Yonghong and his wife Li Haiyan co-founded Haidilao with Zhang Yong and his wife. Ten years later, Zhang Yong had his wife and Shi Yonghong resign from Haidilao's board of directors. The company also acquired the 18% stake in Haidilao held by Shi Yonghong and his wife at the original investment price.</p><p>In my opinion,<b>As the head of Haidilao, Zhang Yong's decision to have his wife and veteran founders step down from the front lines of management is a necessary means of organizational reform for Haidilao. On the one hand, it further downplays the aspect of family management; On the other hand, bringing fresh blood into the top management means the beginning of change.</b></p><p><b>02</b></p><p><b>Crazy expansion</b></p><p><b>What should I pay attention to at Haidilao?</b></p><p>On the evening of August 24, Haidilao released its 2021 semi-annual report. In the first half of the year, the company achieved revenue of 20.094 billion yuan, a year-on-year increase of 105.9%; The company achieved a net profit of 94.529 million yuan, compared to a loss of 965 million yuan in the same period last year, turning a loss into a profit.</p><p>Since February of this year, Haidilao's stock price has been declining steadily, falling by more than 60% compared to its peak. As of the market close on August 25, the company's share price was HK$27.4 per share, with a total market capitalization of HK$149.6 billion. In February of this year, Haidilao's stock price hit a record high of HK$85.8 per share, with a market capitalization of over HK$450 billion.<b>In just six months, more than HK$300 billion evaporated.</b></p><p>Why did the stock price fall? In my opinion, the pandemic, the biggest \"black swan\" event, has had a huge impact on the catering industry. With the pandemic recurring, the capital market is generally pessimistic about industries such as catering, entertainment, and cinema chains, making a decline in stock prices inevitable.</p><p>Since 2020, although the pandemic has had an adverse impact, Haidilao has seized the opportunity to expand against the trend.</p><p><img src=\"https://static.tigerbbs.com/f59b1a42861728038e42b70f76b76f58\" tg-width=\"660\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p><p>By 2019, Haidilao had a total of 768 stores, but in 2020 alone, Haidilao opened 530 new stores. Haidilao's expansion accelerated in the second half of 2020. Among the newly opened stores, 363 were added in the second half of 2020 and 299 were added in the first half of this year. According to media reports, the property management company offered many discounts after the pandemic, and the contract signing was more convenient, which made Haidilao tempted. Especially in third- and fourth-tier cities, local shopping malls offer preferential policies similar to rent-free, resulting in lower opening costs.</p><p>In order to improve performance and couple with the impact of increased costs caused by the pandemic, Haidilao quietly raised prices in April 2020. Some consumers discovered that a serving of freshly fried crispy pork had risen from 28 yuan to 44 yuan. Under public criticism, Haidilao quickly apologized and stated that it would restore the original price. In March of this year, Haidilao replaced the beef cubes in its condiments with plant-based protein \"Flavor Companion,\" and the \"Haidilao Beef Cube Modifier\" has once again plunged it into a media storm.</p><p>In my opinion, expanding against the trend during the pandemic is a correct strategic choice, just like buying at the bottom of the stock market. However, the problem is that opening a store is not just about expanding the hardware; the most important thing is that the supporting facilities, including service, management, and operations, keep up. Many chain retail companies often ultimately fail due to \"rapid expansion\". In the process of expansion, it is necessary to pay attention to at least three core elements:</p><p><b>First, the talent pool.</b>Opening a new store requires a corresponding talent team for terminal stores, and when the density of stores in an area increases, the talent team from the group to regional management needs to be able to keep up.</p><p><b>Second, cost control.</b>Opening a store means a large investment of fixed costs, which is one aspect; On the other hand, if the customer acquisition capabilities of a new store cannot keep up after it opens, the daily operating costs (food waste) will quickly make the new store a \"burden\" for the entire group.</p><p><b>Third, site selection.</b>Rapid store openings and expansion, to some extent, mean that new stores are a mixed bag, with varying degrees of quality. For any chain retail format, location selection is crucial. The biggest taboo is that, from the headquarters' perspective, they often open many stores with unwise locations in order to achieve the number of stores they want to open (thinking they will be popular or should be popular).</p><p><b>03</b></p><p><b>Besides \"service\"</b></p><p><b>What else does Haidilao have?</b></p><p>In June of this year, Zhang Yong pointed out: \"Since its inception, Haidilao has not yet truly established a completely scientific system. For example, in terms of process-oriented operations, when the organization is large, there will be various levels, and each level may violate some rules during operation. Why was Haidilao's system so powerful that it was hyped up online before? Because it was masked by performance.\" And every time I say there's a problem, everyone says I'm being modest.</p><p>As is well known, Haidilao builds its core competitive advantage through service, thus distinguishing itself from other catering brands.</p><p>Over the past 27 years, has Haidilao's USP (Unique Selling Proposition) of \"winning through service\" become outdated? Has the public become aesthetically fatigued with Haidilao?</p><p>My experience is that Haidilao's service is indeed better than any other restaurant, such as kind reminders, handing out heated towels, and providing each person with a small bowl of beef soup. Perhaps Haidilao was criticized for \"excessive service\" in the past, but now it seems that Haidilao has optimized its entire service items and standards, making them more natural and humane.</p><p><img src=\"https://static.tigerbbs.com/a54591efb4c80b81122ed14842f8f5e8\" tg-width=\"660\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p><p>From an objective perspective, Haidilao's service was not excessive and indeed enhanced the overall consumer experience. However, users can accept the cancellation of these services.</p><p>As the leading brand in the hot pot industry, among Sichuan-style hot pot...<b>From the perspectives of its dishes, cost-effectiveness, and taste, Haidilao doesn't seem to be the best.</b>Alternatively, it can be interpreted this way: Haidilao has established a distinction between itself and other Sichuan-style hot pot restaurants through \"service,\" and this distinction has led Haidilao to consciously raise its prices. Therefore, it has established its status as the \"hot pot king\" through \"high-quality service + high prices.\"</p><p>Under this positioning strategy, Haidilao avoided falling into competition with its peers in terms of products. For example, the side dishes in Haidilao's base pot are far inferior to those in Tan Ya Xue, and the dishes—including the main meats, tripe, and soy products—are far inferior to other Sichuan-style hot pots at the same price point. During my time in Chengdu this year, locals generally reported that very few people in Sichuan eat at Haidilao.</p><p>In summary, Haidilao's products themselves do not have a competitive advantage, and on the basis of the same quality, Haidilao's prices are far higher. Haidilao still manages to maintain a good popularity, but it carries the high title of the number one hot pot brand in vain, making it completely unattractive to seasoned foodies.</p><p>For categories like hot pot, deliciousness is naturally the primary factor. I believe Haidilao's consumer motivations fall into two categories:</p><p><b>The first category is trying something new.</b>Go and experience what Haidilao's service is really like.</p><p><b>The second category is the psychology of saving face.</b>。 When the boss brings company employees to gatherings, friends gatherings, birthday celebrations, etc., the prices at Haidilao are acceptable and respectable compared to five-star restaurants.</p><p><b>04</b></p><p><b>Retail Tendency of Catering Enterprises</b></p><p>Haidilao's 2021 semi-annual report also showed two key indicators:</p><p>Haidilao's once-proud table turnover rate has dropped to 3 times per day, which is lower than during the 2020 pandemic. In the first half of 2020, Haidilao's table turnover rate was 3.3 times per day, compared to an average table turnover rate of 3.5 times per day in 2020. Going back further, from 2016 to 2019, Haidilao's table turnover rates were 4.5 times/day, 5.0 times/day, 5.0 times/day, and 4.8 times/day, respectively.</p><p>Haidilao's average customer spending is also declining. In the first half of 2021, Haidilao's average customer spending was 107.3 yuan, compared to 112.8 yuan in the same period of the previous year.</p><p>Data shows that revenue, average order value per person, and table turnover rate are closely related, so the higher the data, the better. However, some industry insiders believe that the catering industry must \"reduce dine-in\" on the road to standardization, encourage takeout, and transform catering businesses into retail enterprises like supermarkets and department stores.</p><p>A 2017 article titled \"Why is Haidilao said to have led the catering industry astray?\" cited...<a href=\"https://laohu8.com/S/MCD\">McDonald's</a>As an example, the article asks: Why is it so difficult to operate in the Chinese catering industry, but McDonald's in the United States has maintained a market value of $100 billion for so many years? I was thinking, since China talks about table turnover rate, could McDonald's have other things besides table turnover rate?</p><p>I thought of scenes in movies where foreigners eat hamburgers, either carrying hamburgers on the street or grabbing something to eat while working overtime. So I asked someone to inquire about McDonald's takeout data. I found that McDonald's takeout data exceeds dine-in data, which means it is a retail industry.</p><p>In my opinion, fast food companies like McDonald's have very limited SKUs, making standardization very convenient. However, for relatively complex restaurants like hot pot (of course, stir-fried food products are even more complex), standardization is not easy, and the possibility of takeout is very low.</p><p>Therefore, it is almost impossible for Chinese restaurants to transform from a catering company into a \"retail company\" like McDonald's (although Haidilao has also launched takeout products such as self-service hot pot, its overall scale is still too small).</p><p><img src=\"https://static.tigerbbs.com/b3fa4873ced5aa075375268cb0520cd9\" tg-width=\"660\" tg-height=\"452\" referrerpolicy=\"no-referrer\"></p><p>So what does the decrease in average order value and table turnover rate mean for Haidilao? My understanding is as follows:</p><p><b>First, the decrease in average order value is not necessarily a bad thing for Haidilao.</b>When Haidilao's \"service\" is no longer absolutely attractive, its high prices will give many competitors an opportunity to take advantage of it. By bringing prices back to a rational level, Haidilao has a comparative advantage, and with the support of its brand power, it can actually attract more consumers.</p><p><b>Second, table turnover rates vary across different restaurant categories.</b>(The table turnover rate of Shaxian snacks is completely different from that of Haidilao), and the table turnover rate does not reflect the strength of the business capabilities (a high table turnover rate does not mean higher revenue per order). To some extent, a longer consumption time may also mean more consumption. Therefore, the table turnover rate indicator has two sides, and the table turnover rate is completely beyond the control of the merchant.</p><p>Finally, in my opinion, Haidilao has been around for 27 years, and the market's sense of novelty has greatly diminished.<b>Product innovation and business model innovation have reached a turning point that must be changed.</b></p>","source":"lsy1614676822040","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why did Haidilao target Zhang Yong's wife and founder?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy did Haidilao target Zhang Yong's wife and founder?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">联商网资讯</strong><span class=\"h-time small\">2021-08-30 08:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Over the years, as a leader in the hot pot industry,<a href=\"https://laohu8.com/S/06862\">Haidilao</a>Life wasn't going very smoothly.</p><p>On June 15, at the shareholders' meeting, someone asked whether Haidilao could continue to grow. Chairman Zhang Yong answered frankly: \"Everyone has mythologized Haidilao, which I personally find very offensive. As Haidilao's largest shareholder, I have no hope.\"</p><p>Zhang Yong said, \"I often say that if you want to know what it means to not live up to its name, just look at Haidilao. We face the same difficulties that all catering companies face; we still haven't solved the problems that all catering companies can't solve.\"</p><p>What Zhang Yong said was the truth and reliability. Of course, it cannot be ruled out that it was paving the way for Haidilao's declining performance and serving as a precaution. Investors should be mentally prepared.</p><p><b>01</b></p><p><b>Personnel changes</b></p><p><b>The team introduced fresh blood</b></p><p>On August 24, Haidilao announced that, effective immediately, Shu Ping had resigned as a non-executive director and member of the audit committee, and Shi Yonghong had resigned as an executive director. Both are the founders of Haidilao, and Shu Ping is the wife of Chairman Zhang Yong.</p><p>Haidilao stated that Shu Ping's resignation was due to an internal organizational restructuring, while Shi Yonghong's was to devote more time and energy to other businesses. Shu Ping became a director of the company in 2015 and was re-designated as a non-executive director in 2018, primarily responsible for overseeing the group's management and strategic development.</p><p>Shi Yonghong is the second-in-command of Haidilao and one of its founders. He became a director of the company in 2015 and was re-designated as an executive director in 2018, primarily responsible for participating in and overseeing the group's management and strategic development. In addition to working for the group, Shi Yonghong is also a hot pot ingredient supplier under Haidilao.<a href=\"https://laohu8.com/S/01579\">Yihai International</a>He is the executive director and chairman of Haidilao and holds director positions in several member companies of Haidilao.</p><p>The announcement also stated that Yang Lijuan has been appointed as the company's deputy CEO, and Cai Xinmin has been appointed as a member of the company's audit committee. Seven new executive directors, Yang Lijuan, Li Peng, Yang Hua, Liu Linyi, Li Yu, Song Qing, and Yang Li, and two new independent non-executive directors, Ma Weihua and Wu Xiaoguang, were added.</p><p>Prior to this appointment, Yang Lijuan was Haidilao's Chief Operating Officer, primarily responsible for overseeing the group's operations. Following this appointment, Yang Lijuan will be responsible for assisting the CEO in managing the group's overall operations.</p><p>In the first half of this year, Haidilao changed its organizational structure, changing the regional coordination coaching model to a large and community management model. Existing stores will be divided into five regions by geographical area, with regional managers coordinating store expansion, engineering, product selection, pricing, and other work within the region. Each district is divided into several communities, and community managers conduct on-site inspections, assessments, and guidance of stores within the area.</p><p>Haidilao stated that it hopes to accurately identify the problems existing in each store through organizational restructuring and provide continuous supervision and guidance.</p><p>According to reports, the new executive directors are all around 40 years old, most of whom were trained by Haidilao from the grassroots level and have rich front-line work experience. Yang Lijuan started her business with Zhang Yong in 1997 and was the first waitress Zhang Yong poached. After Haidilao went public, Yang Lijuan became the \"top waitress,\" holding 179 million shares of the company and a net worth of over 5 billion yuan.</p><p>In 1994, Shi Yonghong and his wife Li Haiyan co-founded Haidilao with Zhang Yong and his wife. Ten years later, Zhang Yong had his wife and Shi Yonghong resign from Haidilao's board of directors. The company also acquired the 18% stake in Haidilao held by Shi Yonghong and his wife at the original investment price.</p><p>In my opinion,<b>As the head of Haidilao, Zhang Yong's decision to have his wife and veteran founders step down from the front lines of management is a necessary means of organizational reform for Haidilao. On the one hand, it further downplays the aspect of family management; On the other hand, bringing fresh blood into the top management means the beginning of change.</b></p><p><b>02</b></p><p><b>Crazy expansion</b></p><p><b>What should I pay attention to at Haidilao?</b></p><p>On the evening of August 24, Haidilao released its 2021 semi-annual report. In the first half of the year, the company achieved revenue of 20.094 billion yuan, a year-on-year increase of 105.9%; The company achieved a net profit of 94.529 million yuan, compared to a loss of 965 million yuan in the same period last year, turning a loss into a profit.</p><p>Since February of this year, Haidilao's stock price has been declining steadily, falling by more than 60% compared to its peak. As of the market close on August 25, the company's share price was HK$27.4 per share, with a total market capitalization of HK$149.6 billion. In February of this year, Haidilao's stock price hit a record high of HK$85.8 per share, with a market capitalization of over HK$450 billion.<b>In just six months, more than HK$300 billion evaporated.</b></p><p>Why did the stock price fall? In my opinion, the pandemic, the biggest \"black swan\" event, has had a huge impact on the catering industry. With the pandemic recurring, the capital market is generally pessimistic about industries such as catering, entertainment, and cinema chains, making a decline in stock prices inevitable.</p><p>Since 2020, although the pandemic has had an adverse impact, Haidilao has seized the opportunity to expand against the trend.</p><p><img src=\"https://static.tigerbbs.com/f59b1a42861728038e42b70f76b76f58\" tg-width=\"660\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p><p>By 2019, Haidilao had a total of 768 stores, but in 2020 alone, Haidilao opened 530 new stores. Haidilao's expansion accelerated in the second half of 2020. Among the newly opened stores, 363 were added in the second half of 2020 and 299 were added in the first half of this year. According to media reports, the property management company offered many discounts after the pandemic, and the contract signing was more convenient, which made Haidilao tempted. Especially in third- and fourth-tier cities, local shopping malls offer preferential policies similar to rent-free, resulting in lower opening costs.</p><p>In order to improve performance and couple with the impact of increased costs caused by the pandemic, Haidilao quietly raised prices in April 2020. Some consumers discovered that a serving of freshly fried crispy pork had risen from 28 yuan to 44 yuan. Under public criticism, Haidilao quickly apologized and stated that it would restore the original price. In March of this year, Haidilao replaced the beef cubes in its condiments with plant-based protein \"Flavor Companion,\" and the \"Haidilao Beef Cube Modifier\" has once again plunged it into a media storm.</p><p>In my opinion, expanding against the trend during the pandemic is a correct strategic choice, just like buying at the bottom of the stock market. However, the problem is that opening a store is not just about expanding the hardware; the most important thing is that the supporting facilities, including service, management, and operations, keep up. Many chain retail companies often ultimately fail due to \"rapid expansion\". In the process of expansion, it is necessary to pay attention to at least three core elements:</p><p><b>First, the talent pool.</b>Opening a new store requires a corresponding talent team for terminal stores, and when the density of stores in an area increases, the talent team from the group to regional management needs to be able to keep up.</p><p><b>Second, cost control.</b>Opening a store means a large investment of fixed costs, which is one aspect; On the other hand, if the customer acquisition capabilities of a new store cannot keep up after it opens, the daily operating costs (food waste) will quickly make the new store a \"burden\" for the entire group.</p><p><b>Third, site selection.</b>Rapid store openings and expansion, to some extent, mean that new stores are a mixed bag, with varying degrees of quality. For any chain retail format, location selection is crucial. The biggest taboo is that, from the headquarters' perspective, they often open many stores with unwise locations in order to achieve the number of stores they want to open (thinking they will be popular or should be popular).</p><p><b>03</b></p><p><b>Besides \"service\"</b></p><p><b>What else does Haidilao have?</b></p><p>In June of this year, Zhang Yong pointed out: \"Since its inception, Haidilao has not yet truly established a completely scientific system. For example, in terms of process-oriented operations, when the organization is large, there will be various levels, and each level may violate some rules during operation. Why was Haidilao's system so powerful that it was hyped up online before? Because it was masked by performance.\" And every time I say there's a problem, everyone says I'm being modest.</p><p>As is well known, Haidilao builds its core competitive advantage through service, thus distinguishing itself from other catering brands.</p><p>Over the past 27 years, has Haidilao's USP (Unique Selling Proposition) of \"winning through service\" become outdated? Has the public become aesthetically fatigued with Haidilao?</p><p>My experience is that Haidilao's service is indeed better than any other restaurant, such as kind reminders, handing out heated towels, and providing each person with a small bowl of beef soup. Perhaps Haidilao was criticized for \"excessive service\" in the past, but now it seems that Haidilao has optimized its entire service items and standards, making them more natural and humane.</p><p><img src=\"https://static.tigerbbs.com/a54591efb4c80b81122ed14842f8f5e8\" tg-width=\"660\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p><p>From an objective perspective, Haidilao's service was not excessive and indeed enhanced the overall consumer experience. However, users can accept the cancellation of these services.</p><p>As the leading brand in the hot pot industry, among Sichuan-style hot pot...<b>From the perspectives of its dishes, cost-effectiveness, and taste, Haidilao doesn't seem to be the best.</b>Alternatively, it can be interpreted this way: Haidilao has established a distinction between itself and other Sichuan-style hot pot restaurants through \"service,\" and this distinction has led Haidilao to consciously raise its prices. Therefore, it has established its status as the \"hot pot king\" through \"high-quality service + high prices.\"</p><p>Under this positioning strategy, Haidilao avoided falling into competition with its peers in terms of products. For example, the side dishes in Haidilao's base pot are far inferior to those in Tan Ya Xue, and the dishes—including the main meats, tripe, and soy products—are far inferior to other Sichuan-style hot pots at the same price point. During my time in Chengdu this year, locals generally reported that very few people in Sichuan eat at Haidilao.</p><p>In summary, Haidilao's products themselves do not have a competitive advantage, and on the basis of the same quality, Haidilao's prices are far higher. Haidilao still manages to maintain a good popularity, but it carries the high title of the number one hot pot brand in vain, making it completely unattractive to seasoned foodies.</p><p>For categories like hot pot, deliciousness is naturally the primary factor. I believe Haidilao's consumer motivations fall into two categories:</p><p><b>The first category is trying something new.</b>Go and experience what Haidilao's service is really like.</p><p><b>The second category is the psychology of saving face.</b>。 When the boss brings company employees to gatherings, friends gatherings, birthday celebrations, etc., the prices at Haidilao are acceptable and respectable compared to five-star restaurants.</p><p><b>04</b></p><p><b>Retail Tendency of Catering Enterprises</b></p><p>Haidilao's 2021 semi-annual report also showed two key indicators:</p><p>Haidilao's once-proud table turnover rate has dropped to 3 times per day, which is lower than during the 2020 pandemic. In the first half of 2020, Haidilao's table turnover rate was 3.3 times per day, compared to an average table turnover rate of 3.5 times per day in 2020. Going back further, from 2016 to 2019, Haidilao's table turnover rates were 4.5 times/day, 5.0 times/day, 5.0 times/day, and 4.8 times/day, respectively.</p><p>Haidilao's average customer spending is also declining. In the first half of 2021, Haidilao's average customer spending was 107.3 yuan, compared to 112.8 yuan in the same period of the previous year.</p><p>Data shows that revenue, average order value per person, and table turnover rate are closely related, so the higher the data, the better. However, some industry insiders believe that the catering industry must \"reduce dine-in\" on the road to standardization, encourage takeout, and transform catering businesses into retail enterprises like supermarkets and department stores.</p><p>A 2017 article titled \"Why is Haidilao said to have led the catering industry astray?\" cited...<a href=\"https://laohu8.com/S/MCD\">McDonald's</a>As an example, the article asks: Why is it so difficult to operate in the Chinese catering industry, but McDonald's in the United States has maintained a market value of $100 billion for so many years? I was thinking, since China talks about table turnover rate, could McDonald's have other things besides table turnover rate?</p><p>I thought of scenes in movies where foreigners eat hamburgers, either carrying hamburgers on the street or grabbing something to eat while working overtime. So I asked someone to inquire about McDonald's takeout data. I found that McDonald's takeout data exceeds dine-in data, which means it is a retail industry.</p><p>In my opinion, fast food companies like McDonald's have very limited SKUs, making standardization very convenient. However, for relatively complex restaurants like hot pot (of course, stir-fried food products are even more complex), standardization is not easy, and the possibility of takeout is very low.</p><p>Therefore, it is almost impossible for Chinese restaurants to transform from a catering company into a \"retail company\" like McDonald's (although Haidilao has also launched takeout products such as self-service hot pot, its overall scale is still too small).</p><p><img src=\"https://static.tigerbbs.com/b3fa4873ced5aa075375268cb0520cd9\" tg-width=\"660\" tg-height=\"452\" referrerpolicy=\"no-referrer\"></p><p>So what does the decrease in average order value and table turnover rate mean for Haidilao? My understanding is as follows:</p><p><b>First, the decrease in average order value is not necessarily a bad thing for Haidilao.</b>When Haidilao's \"service\" is no longer absolutely attractive, its high prices will give many competitors an opportunity to take advantage of it. By bringing prices back to a rational level, Haidilao has a comparative advantage, and with the support of its brand power, it can actually attract more consumers.</p><p><b>Second, table turnover rates vary across different restaurant categories.</b>(The table turnover rate of Shaxian snacks is completely different from that of Haidilao), and the table turnover rate does not reflect the strength of the business capabilities (a high table turnover rate does not mean higher revenue per order). To some extent, a longer consumption time may also mean more consumption. Therefore, the table turnover rate indicator has two sides, and the table turnover rate is completely beyond the control of the merchant.</p><p>Finally, in my opinion, Haidilao has been around for 27 years, and the market's sense of novelty has greatly diminished.<b>Product innovation and business model innovation have reached a turning point that must be changed.</b></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://mp.weixin.qq.com/s/l7-nK7ZKXP7kndgoByHglQ\">联商网资讯</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/23f2c25e060d113f3768c45cafc16292","relate_stocks":{"06862":"海底捞","09988":"阿里巴巴-W"},"source_url":"https://mp.weixin.qq.com/s/l7-nK7ZKXP7kndgoByHglQ","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167910924","content_text":"这些年，作为火锅界的大哥，海底捞的日子过得并不太顺利。\n6月15日，在股东大会上，有人问，海底捞能否持续增长？董事长张勇耿直地回答：“大家神话海底捞了，我本人非常反感。我作为海底捞最大的股东，我是不抱有希望的。”\n张勇说，“我常常讲，要想知道什么是名不符实，看看海底捞就知道了，所有餐饮企业面临的困难，我们同样面临；所有餐饮企业不能解决的问题，我们依然没有解决。”\n张勇所说的是真实靠谱的大实话，当然，也不排除为海底捞的业绩下滑做铺垫，打预防针，对投资人来说，要有个心理准备。\n01\n人事变动\n团队引入新鲜血液\n8月24日，海底捞宣布，自即日起，舒萍辞任公司非执行董事及审计委员会成员，施永宏辞任公司执行董事。这两人都是海底捞的创始人，舒萍是董事长张勇的妻子。\n海底捞表示，舒萍辞任的原因是公司内部组织架构调整，而施永宏则是为了将更多的时间和精力投入到其他业务中。舒萍于2015年成为公司董事，并于2018年调任非执行董事，主要负责监督集团的管理与战略发展。\n施永宏是海底捞的“二把手”，也是创始人之一。其于2015年成为公司董事，并于2018年调任执行董事，主要负责参与并监督集团的管理以及战略发展。除了在集团任职外，施永宏还是海底捞旗下火锅料供应商颐海国际的执行董事及董事长，并在海底捞旗下多个成员公司担任董事职位。\n公告同时表示，杨利娟被任为公司副首席执行官，蔡新民被任为公司审计委员会成员。并新增杨利娟、李朋、杨华、刘林毅、李瑜、宋青、杨立七位执行董事，新增马蔚华、吴宵光两位独立非执行董事。\n杨利娟在此次任命前是海底捞的首席营运官，主要负责监督集团的运营工作。此次任命后，杨利娟将负责协助首席执行官管理集团整体运营工作。\n今年上半年，海底捞变更组织构架，将区域统筹教练模式，改为大、小区管理模式。将现有门店按地域划分为5个大区，由大区经理统筹区域内的门店拓展、工程、选品、定价等工作。每个大区分设若干小区，由小区经理对区域内门店进行现场巡视、考核和辅导。\n海底捞表示，希望通过组织构架的变革，精准识别每家门店存在的问题，并进行持续性的监督和辅导。\n据报道，新的执行董事，年龄都在40岁上下，大多是海底捞从基层培养出来的，有丰富的一线工作经验。杨利娟从1997年起，就跟随张勇一起创业，是张勇挖来的首个服务员。海底捞上市后，杨利娟成为了“最牛服务员”，持有公司1.79亿股，身价超过50亿元。\n1994年，施永宏和妻子李海燕与张勇夫妇共同创立了海底捞。十年后，张勇让妻子和施永宏退出海底捞董事会。并以原始出资价格收购施永宏夫妇所持海底捞18%股权。\n笔者以为，作为海底捞的掌门人，张勇让妻子和元老级创始人一起退出管理一线，对海底捞来说，是组织革新的必要手段。一方面，进一步淡化家族管理的色彩；另一方面，让新鲜血液进入最高管理层，意味着变革的开始。\n02\n疯狂扩张\n海底捞需要注意什么？\n8月24日晚间，海底捞发布2021年半年报。上半年，公司实现营收200.94亿元，同比增长105.9％；实现净利润9452.9万元，较上年同期的亏损9.65亿元，实现扭亏为盈。\n从今年2月以后，海底捞的股价就一路向下，相比最高时，跌去了6成多。截至8月25日收盘，公司股价报27.4港元/股，总市值为1496亿港元。今年2月，海底捞股价创出历史新高，达85.8港元/股，市值超过4500亿港元。仅仅半年，就蒸发3000多亿港元。\n股价为什么下跌？笔者以为，疫情这个最大“黑天鹅”对餐饮行业造成巨大的影响。在疫情不断反反复复的状态之下，资本市场对餐饮、娱乐、院线等行业普遍不看好，股价下跌成为必然。\n从2020年至今，疫情虽然造成不利影响，但海底捞却抓住机会，逆势扩张。\n\n到2019年海底捞共有768家店，但2020年一年，海底捞就新开了530家店。海底捞的扩张提速始于2020年下半年，在新开门店当中，2020年下半年新增363家，今年上半年新增299家。据媒体报道，疫情之后物业给了很多优惠，签约有更高的便利度，这让海底捞无法不心动。尤其在三四线城市，当地商场会提供类似免租的优惠政策，开店成本更低。\n为了提升业绩加之疫情导致的成本提升的影响，2020年4月海底捞悄悄涨价。有消费者发现一份现炸酥肉由28元涨至44元，在舆论的“口诛笔伐”下，海底捞很快致歉并表示恢复原价。今年3月，海底捞将小料中的牛肉粒以植物蛋白“味伴侣”替代，“海底捞牛肉粒变素”让它再次陷入舆论漩涡。\n笔者认为，在疫情期间逆势扩张，是一个正确的战略选择，就跟股市抄底的道理一样。但问题是，开店并不仅仅是在硬件的扩张，服务、管理、营运这一系列的配套跟得上才是最重要的。很多连锁型零售企业，往往最终兵败“快速扩张”。在扩张的过程中，至少需要关注最为核心的三点要素：\n第一、人才队伍。新开一个门店，对于终端门店来说需要相应的人才团队，而当在一个片区门店密度加大之后，从集团到区域化管理的人才队伍都需要能够跟得上。\n第二、成本控制。开店意味着大量的固定成本投入，这是一方面；另一方面，新店运营之后如果获客能力跟不上，日常的运营成本(菜品的损耗)会让新店迅速成为整个集团的“累赘”。\n第三、选址。快速的开店扩张，一定程度上意味着新店泥沙俱下，良莠不齐。对任何连锁零售业态来说，选址至关重要。最为忌讳的是，从总部的角度出发，往往会为了实现开店数量目标，而怀揣侥幸心理(以为能火爆、应该能火爆)地开出不少选址并不明智的门店。\n03\n除了“服务”\n海底捞还有什么？\n张勇在今年6月份曾指出：“海底捞从创业到目前为止，还没有真正建立过完全科学的制度。比如流程化操作方面，组织大了会有各种层级，每个层级在操作中都可能会违反一些制度。为什么之前网上炒作海底捞制度很牛逼？因为被业绩给掩盖了。而且我每次说有问题，大家都说我是谦虚。”\n众所周知，海底捞是以服务打造自己的核心竞争优势，从而区别于其他的餐饮品牌。\n二十七年来，海底捞这种“服务取胜”的USP(独特的销售主张Unique Selling Proposition)过时了吗？大众对海底捞是否已经审美疲劳？\n笔者的体验是，海底捞的服务确实比其他任何一家餐饮都好，比如说善意的提醒，递热毛巾，配好每人一份的小碗牛肉汤等等。也许在过去海底捞饱受“过度服务”的批判，目前来看，海底捞对整个服务项目和标准已经有所优化，更加自然和人性化。\n\n从客观的角度来评价，海底捞的服务没有过度，确实能够为全程的消费体验加分。但是，如果取消掉这些服务，用户也能接受。\n作为火锅赛道的第一品牌，在川派火锅当中，从菜品、性价比和口味三个角度来看，海底捞似乎都不是最佳的。或者可以这么解读，海底捞以“服务”建立了自己与其他川派火锅之间的区隔，而这样的区隔又让海底捞有意识地拉高了自己的定价，所以，以“优质服务+高价位”确立了海底捞“火锅一哥”的身份。\n在这样的定位策略之下，海底捞避免了在产品上陷入与同行的竞争。比如说底锅，海底捞底锅中的配菜远不如谭鸭血，而菜品——包括主打的肉类、毛肚、豆制品等，在同等价位之下远不如其他川派火锅。笔者今年在成都期间，当地人普遍反映，四川很少有人吃海底捞。\n综合分析来看，海底捞的产品本身并没有竞争优势，在同品质的基础上，海底捞的价格远远偏高。而海底捞依然尚能维持不错的热度，只是徒然带着火锅第一品牌的高帽子，对于资深吃货而言，海底捞丝毫没有吸引力。\n对于火锅这样的品类，好吃自然第一要素，海底捞的消费动机，笔者以为可能会有两类：\n第一类，尝鲜，去体验一下海底捞的服务到底是什么样的。\n第二类，面子心理。老板带公司员工聚会，或者朋友聚会，生日庆祝等，海底捞消费，相较于五星级饭店来说价位能接受，也有面子。\n04\n餐饮企业的零售化倾向\n海底捞发布的2021半年报还显示了两项关键指标：\n海底捞一直引以为傲的翻台率跌到了3次/天，比2020年疫情期间还低。2020年上半年，海底捞的翻台率为3.3次/天，2020年的平均翻台率为3.5次/天。再往前追溯，2016年-2019年，海底捞的翻台率分别为4.5次/天、5.0次/天、5.0次/天以及4.8次/天。\n海底捞的顾客人均消费也在下滑。2021年上半年，海底捞的顾客人均消费为107.3元，而上年同期为112.8元。\n从数据上看，营业额跟人均消费客单价跟翻台率紧密相关，数据自然是越高越好。但也有业内人士认为，餐饮在标准化的道路上，必须要实现“降低堂食”，鼓励外卖带走，让餐饮企业变成商超百货一样的零售企业。\n2017年的一篇文章《为什么说海底捞把餐饮行业给带到沟里去了？》举了麦当劳的例子，文章说：为什么中国餐饮这么难做，但是美国的麦当劳1000亿美金市值这么多年？我就思考，中国都讲翻台率，那麦当劳会不会除了翻台率还有其他的？\n我想到一些电影里老外吃汉堡的场景，要么是拎着汉堡在街上吃，要么是加班时候随手拿个吃，我就托人打听麦当劳的外带数据，我发现麦当劳外带的数据超过堂食数据，这代表它是零售业。\n笔者以为，麦当劳这样的快餐企业SKU非常有限，标准化非常方便，但是火锅这样相对比较复杂(当然炒菜类餐饮产品更复杂)的餐饮来说，标准化并不容易，而且外卖的可能性很低。\n所以，中餐企业想要类似麦当劳那样从餐饮企业变成“零售企业”，几乎很难(虽然海底捞也推出了自嗨锅这样的外卖产品，但整体规模毕竟太小了)。\n\n那么客单价和翻台率双双降低，对海底捞意味着什么呢？笔者的理解是这样的：\n第一，客单价的降低对海底捞来说并不一定就是坏事。当海底捞的“服务”不再具有绝对吸引力的时候，高价位会让众多竞争对手有机可乘。让价格回归理性，具有比较优势，在品牌势能的加持之下，海底捞反而可以吸引更多的消费者。\n第二，不同的餐饮品类翻台率各有不同(沙县小吃的翻台率跟海底捞完全不同)，而且翻台率的高低并不能反映经营能力的强弱(翻台率高不代表每一单的营业收入更高)，在某种程度上，消费时间长也可能意味着消费得更多，所以翻台率这个指标具有双面性，而且翻台率也完全不是商家所能控制的。\n最后，笔者以为，已经走过了27年的海底捞，市场对其新鲜体验感已经大大降低，产品创新，模式创新已经到了一个不得不改变的转折点。","news_type":1,"symbols_score_info":{"09988":0.9,"06862":0.9}},"isVote":1,"tweetType":1,"viewCount":3439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810814571,"gmtCreate":1629962150993,"gmtModify":1676530185284,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810814571","repostId":"2162106440","repostType":2,"repost":{"id":"2162106440","kind":"news","pubTimestamp":1629959831,"share":"https://ttm.financial/m/news/2162106440?lang=en_US&edition=fundamental","pubTime":"2021-08-26 14:37","market":"sh","language":"zh","title":"Morgan Stanley: Gives WuXi Biologics \"Overweight\" rating, raises target price 3.6% to HK$170","url":"https://stock-news.laohu8.com/highlight/detail?id=2162106440","media":"智通财经","summary":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。 ...","content":"<p><div>Morgan Stanley released a research report stating that it has given WuXi Biologics (02269) an \"overweight\" rating, raised its target price from HK$164 to HK$170, and raised its earnings forecast for 2021-24 by 1% to 9% to reflect strong first-half performance. Revenue and gross profit forecasts have also been raised accordingly. Follow Tonghuashun Finance (ths518) for more opportunities. Editor: cjh</p><p><a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">Web page link</a></div></p>","source":"tonghuashun","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley: Gives WuXi Biologics \"Overweight\" rating, raises target price 3.6% to HK$170</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley: Gives WuXi Biologics \"Overweight\" rating, raises target price 3.6% to HK$170\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-26 14:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div>Morgan Stanley released a research report stating that it has given WuXi Biologics (02269) an \"overweight\" rating, raised its target price from HK$164 to HK$170, and raised its earnings forecast for 2021-24 by 1% to 9% to reflect strong first-half performance. Revenue and gross profit forecasts have also been raised accordingly. Follow Tonghuashun Finance (ths518) for more opportunities. Editor: cjh</p><p><a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">Web page link</a></div></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16","relate_stocks":{"02269":"药明生物"},"source_url":"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","article_id":"2162106440","content_text":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。\n关注同花顺财经（ths518），获取更多机会\n\n责任编辑：cjh","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":3148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837654134,"gmtCreate":1629886521628,"gmtModify":1676530162487,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837654134","repostId":"2162031026","repostType":2,"repost":{"id":"2162031026","kind":"news","pubTimestamp":1629875170,"share":"https://ttm.financial/m/news/2162031026?lang=en_US&edition=fundamental","pubTime":"2021-08-25 15:06","market":"hk","language":"zh","title":"Zhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments","url":"https://stock-news.laohu8.com/highlight/detail?id=2162031026","media":"智通财经","summary":"智通财经APP获悉，中泰证券发布研究报告称，维持药明生物“买入”评级，认为公司是全球生物药外包服务行业稀缺标的，所处行业高景气、公司优势凸显，后续随着现有项目进入商业化，以及XDC、疫苗、双抗等平台加速兑现，长期空间广阔，未来可期。中泰证券主要观点如下：业绩超预期，归母净利润高于业绩预告。前次业绩预告2021H1归母净利润同比增长135%，实际增长150.3%，高于预期。","content":"<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/600918\">Zhongtai Securities</a>Released a research report saying that maintaining<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Buy\" rating, believing that the company is a scarce target in the global biopharmaceutical outsourcing service industry, with high prosperity in the industry and prominent advantages of the company. Subsequently, with the commercialization of existing projects, XDC, vaccines, double antibodies and other platforms to accelerate the realization, the long-term space is broad, and the future is promising.</p><p><strong>Event:</strong>The company released its results for the first half of 2021, and achieved operating income of 4.41 billion yuan during the period, representing a year-on-year increase of 126.7%; Net profit attributable to the parent was 1.84 billion yuan, a year-on-year increase of 150.3%; The adjusted net profit attributable to the parent was 1.77 billion yuan, a year-on-year increase of 163%.</p><p><strong>The main views of Zhongtai Securities are as follows:</strong></p><p><strong>The performance exceeded expectations, and the net profit attributable to the parent was higher than the performance forecast.</strong></p><p>The previous performance forecast 2021H1 net profit attributable to the parent increased by 135% year-on-year, and the actual growth was 150.3%, which was higher than expected. The Bank believes that it is mainly due to:</p><p>1) The volume of late clinical and commercialization projects increased rapidly, including the clinical stage revenue of 1.94 billion yuan (+109.2% year-on-year) and the commercialization stage revenue of 889 million yuan (+2923.5%);</p><p>2) the rapid recovery of demand after the normalization of overseas epidemic, with revenue from North America of RMB2.19 billion (+149.3% year-on-year) and revenue from Europe of RMB990 million (+706.8% year-on-year) in 2021H1;</p><p>3) continuous optimization of management capabilities and continuous improvement of operational efficiency, with gross profit margin of approximately 52.1% (+11.6pp), net profit margin of approximately 41.8% (+3.9pp) and period expense ratio of approximately 12.4% (-8.2pp) in 2021H1;</p><p>4) Low base last year: In the first half of last year, the overall base was low due to the epidemic disturbance, with 740 million (+63.6%) attributable to the parent in 2020H1. However, compared with the net profit attributable to the parent in 2019H1, the company's CAGR from 2019H1 to 2021H1 was about 102.3%, with a rapid growth.</p><p><strong>CMO's logic of heavy volume continues to be realized, and the strategy of following and winning molecules is progressing smoothly, which is expected to accelerate the growth of overall performance.</strong></p><p>Adhering to the strategy of following and winning molecules, as of June 30, the company extended 27 projects (14 pre-clinical to clinical, 2 phase III to commercial) in the first half of the year, introduced 20 clinical projects externally (+400%, including 9 clinical phase II and 4 clinical phase III), added 79 projects, and the overall number of projects reached 408 (+42.7% year-on-year compared with 2020H1), including 212 pre-clinical (+50.4%), 160 early (phase I and phase II) projects (+28%), 32 phase III projects (+68.4%), and 4 commercial projects (three new).</p><p>In addition, due to the rapid growth of the number of projects, the company's orders in hand continue to increase rapidly. It is expected that in the next three years, the total amount of orders completed will reach 2.25 billion USD (+143.1%), and the total amount of uncompleted orders will be about 12.46 billion USD (+31.7%), of which the outstanding service orders will be 7.23 billion USD (+25.2%). It is expected that the bank will have seven commercialization projects in 2021, which is expected to promote a new round of heavy volume in the CDMO sector and accelerate the overall performance growth.</p><p><strong>Advanced XDC, vaccine and dual antibody platforms bring new growth momentum.</strong></p><p><strong>XDC:</strong>The company's XDC drug R&D platform has undertaken 48 ADC projects (+60%) with the advantages of WuXiDAR4 technology, and 15 CDMO projects are already underway, and the commercialization volume can be expected;</p><p><strong>WuxiVaccine:</strong>Nine vaccine orders are being executed (up 8 year-on-year), and the orders in hand have increased to US$3.3 billion. WuXi Haide is expected to be put into operation in 2022, which is expected to continue to bring incremental performance.</p><p><strong>Double antibody:</strong>WuxiBody ™ Undertake 31 projects (+19.2%), and expect to add 1~2 IND applications in 2021, which is expected to extend CDMO to gradually contribute new increments.</p><p><strong>Earnings Forecast and Investment Advice:</strong>The bank estimates that the company's revenue from 2021 to 2023 will be 9.36, 13.84 and 19.4 billion yuan, representing a year-on-year increase of 66.7%, 47.9% and 40.2%, and the net profit attributable to the parent will be 2.82, 4.17 and 5.88 billion yuan, representing a year-on-year increase of 67.1%, 47.6% and 41.2%, corresponding to EPS of 0.67, 0.98 and 1.39 yuan.</p><p><strong>Risk warning events:</strong>The public information used in the research report may be subject to the risk of information lag or updating in a timely manner, proposed acquisition<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>The risks of the progress of China's biologics production base project being less than expected, the investment in biologics research and development being less than expected, and the risk of loss of core technical personnel.</p><p></body></html></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-25 15:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/600918\">Zhongtai Securities</a>Released a research report saying that maintaining<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Buy\" rating, believing that the company is a scarce target in the global biopharmaceutical outsourcing service industry, with high prosperity in the industry and prominent advantages of the company. Subsequently, with the commercialization of existing projects, XDC, vaccines, double antibodies and other platforms to accelerate the realization, the long-term space is broad, and the future is promising.</p><p><strong>Event:</strong>The company released its results for the first half of 2021, and achieved operating income of 4.41 billion yuan during the period, representing a year-on-year increase of 126.7%; Net profit attributable to the parent was 1.84 billion yuan, a year-on-year increase of 150.3%; The adjusted net profit attributable to the parent was 1.77 billion yuan, a year-on-year increase of 163%.</p><p><strong>The main views of Zhongtai Securities are as follows:</strong></p><p><strong>The performance exceeded expectations, and the net profit attributable to the parent was higher than the performance forecast.</strong></p><p>The previous performance forecast 2021H1 net profit attributable to the parent increased by 135% year-on-year, and the actual growth was 150.3%, which was higher than expected. The Bank believes that it is mainly due to:</p><p>1) The volume of late clinical and commercialization projects increased rapidly, including the clinical stage revenue of 1.94 billion yuan (+109.2% year-on-year) and the commercialization stage revenue of 889 million yuan (+2923.5%);</p><p>2) the rapid recovery of demand after the normalization of overseas epidemic, with revenue from North America of RMB2.19 billion (+149.3% year-on-year) and revenue from Europe of RMB990 million (+706.8% year-on-year) in 2021H1;</p><p>3) continuous optimization of management capabilities and continuous improvement of operational efficiency, with gross profit margin of approximately 52.1% (+11.6pp), net profit margin of approximately 41.8% (+3.9pp) and period expense ratio of approximately 12.4% (-8.2pp) in 2021H1;</p><p>4) Low base last year: In the first half of last year, the overall base was low due to the epidemic disturbance, with 740 million (+63.6%) attributable to the parent in 2020H1. However, compared with the net profit attributable to the parent in 2019H1, the company's CAGR from 2019H1 to 2021H1 was about 102.3%, with a rapid growth.</p><p><strong>CMO's logic of heavy volume continues to be realized, and the strategy of following and winning molecules is progressing smoothly, which is expected to accelerate the growth of overall performance.</strong></p><p>Adhering to the strategy of following and winning molecules, as of June 30, the company extended 27 projects (14 pre-clinical to clinical, 2 phase III to commercial) in the first half of the year, introduced 20 clinical projects externally (+400%, including 9 clinical phase II and 4 clinical phase III), added 79 projects, and the overall number of projects reached 408 (+42.7% year-on-year compared with 2020H1), including 212 pre-clinical (+50.4%), 160 early (phase I and phase II) projects (+28%), 32 phase III projects (+68.4%), and 4 commercial projects (three new).</p><p>In addition, due to the rapid growth of the number of projects, the company's orders in hand continue to increase rapidly. It is expected that in the next three years, the total amount of orders completed will reach 2.25 billion USD (+143.1%), and the total amount of uncompleted orders will be about 12.46 billion USD (+31.7%), of which the outstanding service orders will be 7.23 billion USD (+25.2%). It is expected that the bank will have seven commercialization projects in 2021, which is expected to promote a new round of heavy volume in the CDMO sector and accelerate the overall performance growth.</p><p><strong>Advanced XDC, vaccine and dual antibody platforms bring new growth momentum.</strong></p><p><strong>XDC:</strong>The company's XDC drug R&D platform has undertaken 48 ADC projects (+60%) with the advantages of WuXiDAR4 technology, and 15 CDMO projects are already underway, and the commercialization volume can be expected;</p><p><strong>WuxiVaccine:</strong>Nine vaccine orders are being executed (up 8 year-on-year), and the orders in hand have increased to US$3.3 billion. WuXi Haide is expected to be put into operation in 2022, which is expected to continue to bring incremental performance.</p><p><strong>Double antibody:</strong>WuxiBody ™ Undertake 31 projects (+19.2%), and expect to add 1~2 IND applications in 2021, which is expected to extend CDMO to gradually contribute new increments.</p><p><strong>Earnings Forecast and Investment Advice:</strong>The bank estimates that the company's revenue from 2021 to 2023 will be 9.36, 13.84 and 19.4 billion yuan, representing a year-on-year increase of 66.7%, 47.9% and 40.2%, and the net profit attributable to the parent will be 2.82, 4.17 and 5.88 billion yuan, representing a year-on-year increase of 67.1%, 47.6% and 41.2%, corresponding to EPS of 0.67, 0.98 and 1.39 yuan.</p><p><strong>Risk warning events:</strong>The public information used in the research report may be subject to the risk of information lag or updating in a timely manner, proposed acquisition<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>The risks of the progress of China's biologics production base project being less than expected, the investment in biologics research and development being less than expected, and the risk of loss of core technical personnel.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/543594.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{"600918":"中泰证券","02269":"药明生物"},"source_url":"http://www.zhitongcaijing.com/content/detail/543594.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162031026","content_text":"智通财经APP获悉，中泰证券发布研究报告称，维持药明生物(02269)“买入”评级，认为公司是全球生物药外包服务行业稀缺标的，所处行业高景气、公司优势凸显，后续随着现有项目进入商业化，以及XDC、疫苗、双抗等平台加速兑现，长期空间广阔，未来可期。事件：公司发布2021年上半年业绩，期内实现营业收入44.1亿元，同比增长126.7%;归母净利润18.4亿元，同比增长150.3%;经调整归母净利润17.7亿元，同比增长163%。中泰证券主要观点如下：业绩超预期，归母净利润高于业绩预告。前次业绩预告2021H1归母净利润同比增长135%，实际增长150.3%，高于预期。该行认为主要源于：1)临床后期及商业化项目快速放量，其中临床阶段收入19.4亿元(同比+109.2%)，商业化阶段收入8.89亿(+2923.5%);2)海外疫情常态化后需求的快速恢复，2021H1北美收入21.9亿元(同比+149.3%)，欧洲收入9.9亿元(同比+706.8%);3)管理能力持续优化，运营效率持续提升，2021H1毛利率约为52.1%(+11.6pp)，净利率约为41.8%(+3.9pp)，期间费用率约12.4%(-8.2pp);4)去年基数低：去年上半年因疫情扰动导致整体基数较低，2020H1归母7.4亿(+63.6%)，但对比2019H1归母净利润，公司2019H1-2021H1CAGR约102.3%，增长迅猛。CMO放量逻辑持续兑现，跟随并赢得分子策略进展顺利，有望带动整体业绩加速增长。公司秉承跟随及赢得分子策略，截止6月30日，上半年延伸27个项目(14个临床前至临床、2个III期至商业化)，外部引进20个临床项目(+400%，其中临床II期9个、临床III期4个)，新增79个项目，整体项目数达408个(较2020H1同比+42.7%)，其中临床前212个(+50.4%)、早期(I期、II期)项目数达160个(+28%)，III期项目达32个(+68.4%)，商业化项目4个(新增三个)。此外，源于项目数不断快速增长，公司在手订单持续高增，预计未来三年能够完成订单总额达22.5亿美元(+143.1%)，未完成订单总额约124.6亿美元(+31.7%)，其中未完成服务订单72.3亿美元(+25.2%)。该行预计2021年将有7个商业化项目落地，有望推动CDMO板块新一轮放量，带动整体业绩提速增长。先进的XDC、疫苗、双抗平台带来增长新动能。XDC：公司XDC药物研发平台凭借WuXiDAR4技术优势承接48个ADC项目(+60%)，已有15个CDMO项目正在进行，商业化放量可期;WuxiVaccine：9个疫苗订单正在执行(同比增长8个)，在手订单提升至33亿美元，药明海德预计2022年投入运营，有望持续带来业绩增量。双抗：WuxiBody™承接31个项目(+19.2%)，预计2021年新增1~2个IND申请，有望延伸CDMO逐步贡献新增量。盈利预测与投资建议：该行预计2021-2023年公司收入93.6、138.4和194亿元，同比增长66.7%、47.9%、40.2%，归母净利润28.2、41.7和58.8亿元，同比增长67.1%、47.6%、41.2%，对应EPS为0.67、0.98、1.39元。风险提示事件：研究报告使用的公开资料可能存在信息滞后或更新不及时的风险、拟收购辉瑞中国生物药生产基地项目进展不及预期风险、生物药研发投入不及预期、核心技术人员流失的风险。","news_type":1,"symbols_score_info":{"600918":1,"02269":1}},"isVote":1,"tweetType":1,"viewCount":4139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}